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Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new drug approvals and a
massive pipeline of additional treatments in clinical and preclinical development. However, modulation of the
immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-
speciﬁc systemic inﬂammation and autoimmune side effects. Drug delivery technologies have an important
role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities.
Here we review mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss approaches
based indrug delivery technology to enhance the safety andpotencyof these treatments. These include strategies
tomerge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune
cells, and localizing therapeutics intratumorally. Rational design employing lessons learned from the drug deliv-
ery and nanomedicine ﬁelds has the potential to facilitate immunotherapy reaching its full potential.
© 2017 TheAuthors. Publishedby Elsevier B.V. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Immunotherapies, treatments that modulate the immune system,
have long been proposed as a potentially powerful approach to “func-
tional” or actual cures of disease, based on the natural function of the
immune system in protecting thehost and its cardinal features of poten-
cy, speciﬁcity, and memory [1]. Motivated by these features, immuno-
therapies are now in preclinical and clinical development for
treatment of diverse infectious diseases, autoimmunity, allergies, trans-
plant rejection, graft vs. host disease, and cancer. Among these thera-
peutic areas, cancer immunotherapy in particular has experienced
dramatic recent progress in the clinic [2,3]. For many years, cancer im-
munotherapies were plagued by high toxicity, low to negligible efﬁcacy,
or both. However, steady advances in fundamental cancer immunology
and translational immunotherapy have now led to two classes of treat-
ment with signiﬁcant impact in advanced cancer patients – adoptive
cell therapy (ACT), based on the injection of autologous tumor-directed
T cells [4,5]; and checkpoint blockade, treatment with antibodies that
block the inhibitory receptors cytotoxic T lymphocyte antigen-4 (CTLA-
4) or programmed death-1 (PD-1, or its counter-receptors PD-L1/PD-
L2) [6,7]. ACT therapy in patients with advanced metastatic melanoma
and several hematologic cancers has shown a high proportion of com-
plete responses (complete elimination of detectable tumor burden),
some of which are durable responses lasting many years [8]. Treatment
with ipilimumab, a fully human anti-CTLA-4 antibody, has led to com-
plete responses in approximately 20% of advanced melanoma patients,
with durations lasting N10 years [9]. Treatment with PD-1 blocking anti-
bodies has elicited objective responses in a variety of solid tumors includ-
ingmelanoma, lung cancer, prostate cancer, breast cancer, ovarian cancer,
head and neck cancer, and a subset of colorectal cancers [6]. Reﬂecting
their complementary modes of action, combination therapy with anti-
CTLA-4 and anti-PD1 has led to even greater response rates in melanoma
patients, where a signiﬁcant fraction of patients exhibit complete tumor
regressions in a space of ~10 weeks [10,11].
These ﬁndings have energized the ﬁeld and motivated a massive ef-
fort to further explore combination immunotherapies that optimally
arm the immune system against metastatic disease, but the power of
the immune system creates the potential for not only a dramatic attack
on tumors but also a signiﬁcant danger to healthy tissues. For example,
monotherapy with anti-CTLA-4, which both blocks a negative regulato-
ry signal during T cell activation and inhibits the function of regulatory T
cells, leads to a series of autoimmune side effects, including gastrointes-
tinal toxicity, pruritis, and fatigue, side effects which become grade 3 or
4 serious adverse events in ~23% of patients [12]. When anti-CTLA-4 is
combined with anti-PD-1, enhanced anti-tumor activity comes at the
cost of synergistically exacerbated toxicity; ~55% of previously untreat-
ed melanoma patients given the combination experienced grade 3 or 4
adverse events [11,12]. As discussed in detail in this review, serious tox-
icities are characteristic of a broad range of immunomodulatory drugs.
Thus, a looming challenge in the ﬁeld is the development of effective
strategies to harness the potential of combination treatments while
avoiding debilitating toxicities that prevent immunotherapies from
reaching their full curative potential. Clinical studies are already under-
way seeking to optimize timing and dosing to limit the toxicity of these
promising immunotherapy drugs, but in the setting of intravenous ad-
ministration – believed to be key for systemically modulating the im-
mune response against disseminated tumors – dosing schedules with
high safety and high efﬁcacy are often diametrically opposed.
In this review, we discuss the potential for drug delivery technolo-
gies spanning a range of approaches to enhance immunotherapies,
with a particular emphasis on the potential for enhancing the safety of
immunomodulatory drugs. We ﬁrst review representative mechanisms
of immune toxicity from immunotherapy agents of both clinical and
preclinical interest, separating systemic and local (i.e. intratumoral)
drug administration issues. We then discuss approaches to ameliorate
these toxicities based in concepts from the ﬁeld of drug delivery,
employing technologies ranging from nanoparticles to synthetic biolo-
gy. The immune system as a target for therapy presents several chal-
lenges and opportunities relative to somatic tissues: Immune cells
circulate through the blood, creating the potential for efﬁcient direct
targeting of therapeutics to these cells (relative to, for example,
targeting drugs to tumor cells); and immune cells proliferate, providing
a source for self-ampliﬁcation of small doses of appropriately-targeted
drugs. However, there is a need to direct immunomodulatory drugs to
tumor-speciﬁc cells rather than stimulating the entire leukocyte com-
partment non-speciﬁcally, and these cells may be preferentially
enriched at tumor sites and tumor-draining lymph nodes. There are
thus both challenges and opportunities for the ﬁeld of drug delivery to
impact cancer immunotherapy.
2. Mechanisms of toxicity elicited by immunotherapy drugs
To rationally approach strategies for increasing the safety of system-
ic immunotherapies, an understanding of mechanisms underlying the
toxicity of systemically-administered immunoregulatory drugs is need-
ed. In this section, we review the mechanisms of toxicity underlying
several important classes of immunotherapy agents: interleukin-2, rep-
resentative of several important γ-chain cytokines that promote lym-
phocyte proliferation and effector function; agonistic antibodies
against the costimulatory receptors CD137 (also known as 41BB) and
CD28, representative of agonistic antibodies against lymphocyte co-
stimulatory molecules; and the checkpoint blockade agents anti-CTLA-
4 and anti-PD-1. A discussion of all immunoregulatory agents in preclin-
ical and clinical testing for cancer immunotherapy is beyond the scope
of any single review, but these example biologics represent 3 important
distinctmechanisms of immunomodulation relevant tomuch of the on-
going clinical development of immunotherapy.
2.1. Interleukin-2 as a paradigm for approved but toxic immunotherapy
Systemic high-dose interleukin-2 (IL-2) was one of the ﬁrst immuno-
therapy agents to be licensed for cancer therapy, approved by the FDA for
metastatic melanoma and renal cell carcinoma (RCC) treatment in 1992.
IL-2 was ﬁrst isolated as a factor promoting the growth of activated T
cells, but also stimulates natural killer (NK) cells, both ofwhichmotivated
its use as a cancer therapeutic. However, it is now also conversely known
to also promote activation-induced cell death of stimulated T cells and
maintains the survival and function of regulatory T-cells, which restrain
the effector armsof the immune system tomaintain tolerance andprotect
healthy tissues fromautoimmune attack [13]. Interleukin-2 biology is fur-
ther complicated by the nature of its tripartite receptor, which is com-
prised of the IL-2R α chain (CD25), β chain (CD122), and common γ
chain (CD132) [13]. Differential expression of the three components of
the IL-2R leads to different signaling and functional outcomes on different
cell types at different stages of activation.
Based on dosing schedules established clinically in the 1980s, IL-2 is
approved as a “high dose” (HD) IL-2 therapy for melanoma and RCC ad-
ministered intravenously every 8 h for up to 14 total doses [14]. Although
much is made in the current renaissance of cancer immunotherapy
around the “tail of the curve” effect, where a small proportion of patients
treated with checkpoint blockade become long-term survivors [9], such
durable increases in survival were already seen in the early 1990s in pa-
tients treated with IL-2, where ~12% of patients treated with HDIL-2 at
the National Cancer Institute had survival of at least 10 years [14]. Al-
thoughHDIL-2 elicits objective responses in ~16% of patients, it is also ex-
tremely toxic. The very short half-life of IL-2 (~12 min [15]) leads to a
requirement for high doses to be administered in order for functional
levels to be maintained for a sufﬁcient timespan. High level dosing in
turn leads to dose-related toxicities including vascular leak syndrome
(VLS) and cytokine release syndrome, amassive systemic cytokine release
and inﬂammatory reaction caused by IL-2 immune stimulation [16]; le-
thal adverse events were found in 2% of patients [14]. These issues
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mean that IL-2 therapy requires careful selection of patientswith analyses
of baseline cardiac risk factors, performance status, and biomarker analy-
sis. IL-2's modes of action in expanding T-cells and NK cells make it a log-
ical candidate for combination immunotherapies, but lethal toxicities
were seen when HDIL-2 was administered after checkpoint blockade
[17] or tyrosine kinase inhibitor (TKI) therapy [18].
The toxicity of IL-2 is multifactorial and involves a complex set of in-
teractions, most notably between immune cells and the vascular endo-
thelium. IL-2 therapy has an acute impact on circulating effector
lymphocytes, with a rapid transient induction of lymphopenia. IL-2-acti-
vated cells strongly bind to endothelial cells (ECs), leading to endothelial
cell cytotoxicity byNK cells and granulocytes [19–21]. In addition, IL-2-in-
duced pulmonary edema is promoted by the interaction of IL-2with func-
tional IL-2 receptors (IL-2R) expressed on lung endothelial cells; blocking
IL-2 interactionswith IL-2Rα (CD25) abrogates IL-2-mediated pulmonary
edema [22–24]. The endothelial cell damage causedby IL-2-activatedhost
effector cells and/or cytokines and chemokines released in response to IL-
2 (e.g., IFN-γ and TNF-α) contribute to VLS and systemic toxicity [25–30].
The role of cytokines in the development of VLS is related to both their di-
rect effect on increasing the permeability of the vascular endotheliumand
their effects on leukocyte and EC activation [31]. Activation of both ECs
and monocytes/neutrophils by cytokines results in the release of large
amounts of nitric oxide (NO) [32,33], which further damage ECs and en-
hance the adhesion of neutrophils through upregulation of adhesion
receptors [34]. Administration of NO inhibitors has been reported to de-
crease IL-2-induced vascular toxicity in mice [30], and it has been
shown that NK cell depletion protects mice from IL-2-induced VLS [35,
36]. Neutrophils also play a critical role in VLS by adhering to ECs and
inducing lysis via reactive oxygen intermediates (ROI) and proteases
[32,37,38]. IL-2 also leads to complement activation which induces mast
cell degranulation, resulting in the release of vasoactive mediators and
an increase in vascular permeability [39].
The efﬁcacy of IL-2 has fueledmuch interest in strategies to mitigate
its toxicity, as discussed in the subsequent sections below. Continuous
intravenous infusion of low dose IL-2 is less toxic than bolus injection
of high dose IL-2, but the therapeutic efﬁcacy is also compromised [40,
41]. Strategies strictly localizing IL-2 to tumors or tumor-draining
lymph nodes (discussed further below) lack the toxicity of i.v. adminis-
tration [42–44], suggesting that IL-2's toxicity is linked to systemic ex-
posure. Thus, approaches to target IL-2 to speciﬁc cell types, engineer
its interaction with different cell subsets, or localize it to tumors are all
strategies of interest to improve its therapeutic index.
2.2. Checkpoint blockade
For many in the general clinical oncology world, the real break-
through in cancer immunotherapy came with the results from recent
clinical trials of so-called “checkpoint blockade” antibodies – antibodies
that block negative regulatory signals restraining the host T-cell re-
sponse against tumors. Twowell studied checkpoint receptors, cytotox-
ic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1),
are expressed on T-cells and act to diminish responses in early activated
and mature peripherally disseminated T-cells, respectively. T-cells are
activated when the T-cell receptor binds peptide presented in the
major histocompatibility complex on antigen presenting cells (APCs, es-
pecially dendritic cells) and costimulatory receptors on the T-cell and
APC are co-ligated (e.g., CD28 on the T-cell binding to CD80 and CD86
on APCs). CTLA-4 is upregulated on T-cells during early stages of activa-
tion, with expression increasing around 2 days after encounter with
cognate peptide presented on APCs in lymphoid organs [12]. As a high
CD80/86CD28
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Fig. 1.Mechanisms of action for immunomodulatory antibodies. (A) T-cells are activated by APCs presenting speciﬁc peptide-MHC complexes in tandem with signals from both positive
(e.g., CD28, CD137) and negative (e.g., CTLA-4) costimulatory receptors binding cognate partners on the APC surface. Anti-CTLA-4 blocks receipt of negative regulatory signals fromCTLA-4
engagement to boost T-cell priming by APCs. (B) Anti-PD-1 augments T-cell function in the effector phase by blocking negative regulatory signals delivered by PD-L1 expressed on tumor
cells or PD-L2 expressed byAPCs and other cells. Anti-CD137 can also boost T-cell effector function through crosslinking of theCD137 costimulatory receptor and/or clustering receptors by
antibody displayed on APCs through their Fcγ receptors. (C) Inmurinemodels antibodies have beenutilized to bind cells and initiate their depletion/killing through complementmediated
cytotoxicity and antibody dependent cellular cytotoxicity (ADCC). Thismechanism can be applied directly to tumor cells. Anti-CTLA-4 antibodies also act to boost the immune response by
triggering ADCC-mediated depletion of intratumoral Tregs that express high levels of CTLA-4 receptor.
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afﬁnity homologue of CD28, CTLA-4 serves to interrupt costimulation
signals from CD28 to the newly activated T-cells by competition for
CD28's ligands, and thereby dampens the immune response (Fig. 1A)
[45]. Inhibition of CTLA-4 usingmonoclonal antibodies lifts the inhibito-
ry effects of CTLA-4, but only on activated T-cells [46]. In addition, CTLA-
4 is highly expressed on regulatory T cells (Tregs); therefore, in mice,
administration of anti-CTLA-4 antibodies has been shown to deplete
Tregs speciﬁcally from the tumor microenvironment where CTLA-4 is
most highly expressed by these cells ([47–49]. In contrast to CTLA-4,
PD-1 is primarily expressed on T cells in the periphery and in the
tumor microenvironment (Fig. 1B) [12]. Interaction with one of its
two ligands (PD-L1 or PD-L2) downregulates antigen receptor signaling
in mature T-cells and decreases the expression of pro-inﬂammatory cy-
tokines. PD-1 expression is present during T-cell effector phases and on
re-exposure to antigen [50]. Blockade of the PD-1 interaction with its li-
gand can transiently reverse exhaustion of T-cells in the periphery [51].
These distinctmechanisms of action have led to therapeutic blocking
antibodies targeting CTLA-4, PD-1, or PD-1's ligands. Ipilimumab, an an-
tibody that blocks CTLA-4was approved in 2011 following a pivotal trial
demonstrating its ability to improve long term overall survival in ad-
vancedmetastaticmelanoma - the ﬁrst newdrug for advancedmelano-
ma approved in N30 years [52]. Ipilimumab therapy leads to complete
tumor regressions lasting at least 10 years in ~20% of treatedmelanoma
patients [9]. Following on the heels of ipilimumab's approval, several
antibodies blocking PD-1 (expressed by T-cells) binding to its ligands
PD-L1 or PD-L2 (expressed by many cells, including tumor cells) – en-
tered the clinic and have shown evenmore impressive initial responses,
with 30–50% of patients in diverse diseases ranging from melanoma to
lung cancer exhibiting objective tumor regressions [53–55]. The ability
of PD-1 blockade to elicit responses in solid tumors not previously
viewed as “immunogenic” (e.g., lung cancer) heralded a new era of
promise for immunotherapies. However, “taking the brakes off” of the
immune system with systemic checkpoint blockade, leads (not unex-
pectedly) to toxicities, which are ampliﬁed when these drugs are
employed in combination.
Ipilimumab therapy elicits adverse events, with 60–65% of patients
experiencing immune related adverse events (irAEs) at a moderate
dose of 3 mg/kg every three weeks [52,56]. In two large clinical trials,
the most common adverse events included pruritus (25–35%), diarrhea
(23–33%), rash (15–33%), and fatigue (15–28%) [11,57]. Serious Grade 3
and 4 adverse events occur in 20–27% of patients, the most frequent
being gastrointestinal toxicities resulting in enterocolitis and diarrhea
(6–8% of grade 3–4 events) [11]. Of the 14 patients who died in the
phase III clinical trial mentioned above, 7 died due to immune-related
adverse events [11,52,56,57]. Overall, ipilimumab elicits broad irAEs of
the skin, gastrointestinal tract, and endocrine system.
Anti-CTLA-4 irAEsmaymanifest from depletion of regulatory T cells,
as evidenced by the need for depleting antibody isotypes (such as
IgG2a) capable of engaging Fcγ receptors to mediate antitumor activity
in mouse models [48,58,59]. CTLA-4 blocking antibodies of IgG2a
isotype yielded depletion of regulatory T-cells at tumor sites (Fig. 1C)
and an increase in CD8+ T effector cells in the periphery, while other
isotypes expanded both regulatory and effector T-cells in the periphery
[59]. Some evidence however demonstrates that the depletion of regu-
latory T-cells is context speciﬁc and limited to the tumormicroenviron-
ment, due to the high frequency of Fcγ receptor-expressing tumor
associated macrophages, though depletion of regulatory T-cells in the
periphery remains conceivable [48]. Regulatory T-cells are known to
maintain tolerance and restrict lymphocytic inﬁltration to mucosal lin-
ings of organs including the lungs and gastrointestinal tract [60]. Deple-
tion of such regulatory T-cells in the intestines may account for
increased intraepithelial lymphocytes and leukocyte inﬁltration in the
lamina propria of ipilimumab-treated patients as revealed by endoscop-
ic analysis, thus causing irAEs such as diarrhea [61,62].
PD-1 blockade antibodies have in general shown less serious side ef-
fects compared to anti-CTLA-4 in humans, with only ~15% of patients
experiencing serious adverse events, primarily pneumonitis. For com-
parison, in phase I dose escalation studies, administration of nivolumab
(one of the approved anti-PD-1 antibodies) resulted in grade 3–4 ad-
verse events in only 14% of patients compared to the 20–27% in early
ipilimumab trials. Lastly, irAEs of any grade affected only 41% of patients
compared to ipilimumab's 60–65% [63]. Consistent with their distinct
mechanisms of action, the immune related adverse events differ be-
tween anti-CTLA-4 and anti-PD-1/PD-L1 therapeutics: anti-PD-1 irAEs
include rash, hypothyroidism, hyperthyroidism, pneumonitis, diarrhea,
and elevated aminotransferase levels [12]. A large phase III trial con-
ﬁrmed that both nivolumab and pembrolizumab (both now clinically
approved anti-PD-1 antibodies) induce fewer adverse events than
ipilimumab [64].
Mechanistic differences between PD-1 and CTLA-4 receptors are
likely responsible for thedifferences in adverse outcomes andbetter tol-
erability of PD-1 checkpoint blockade. Given that CTLA-4 is expressed
on all T cells around the time of activation in lymphoid tissue, broad
spectrum autoimmunity can result from blockade of CTLA-4. Addition-
ally, as noted above administration of anti-CTLA-4 antibodies in mice
depletes regulatory T cells, which play an important role in restraining
autoimmune attack of host tissue [12], and systemic depletion of Tregs
leads to fatal autoimmune pathology. Such a mechanism would moti-
vate strategies to localize the action of anti-CTLA-4 in vivo, but this phe-
nomenon remains unconﬁrmed in humans so far. Unlike CTLA-4, the
PD-1 receptor is largely expressed on antigen re-exposed cells in the pe-
riphery; therefore, a smaller pool of T-cells are likely affected by treat-
ment with anti-PD-1 antibodies. Because expression of CTLA-4 is
dependent on initial priming of T-cells, the onset of irAEs and therapeu-
tic efﬁcacy from anti-CTLA-4 antibodies is often delayed compared to
PD-1 blockade, which reactivates T-cells already present in the tumor
microenvironment [12]. The varying populations of T-cells targeted by
checkpoint blockade antibodies may explain the severity and time to
onset of immune-related adverse events.
CTLA-4 and PD-1 are just the ﬁrst successfully targeted inhibitory re-
ceptors on lymphocytes, two members of a large collection of negative
regulatory receptors expressed by T-cells. A non-exhaustive list of T-
cell-expressed negative regulatory receptors explored in preclinical
studies and clinical trials includes Lymphocyte activation gene 3 (LAG-
3), T cell membrane protein 3 (TIM-3), T-cell immunoreceptor with im-
munoglobulin and ITIM domains (TIGIT), V-domain Ig suppressor of T-
cell activation (VISTA), adenosine A2a receptor (A2aR), and B and T
lymphocyte attenuator (BTLA) [65–68]. In addition, because of their dis-
tinct mechanisms of action (despite their classiﬁcation together in the
immune-oncology world as checkpoint blockade agents), therapies
combining anti-CTLA-4 and anti-PD-1 were obvious to explore, and
showed promising synergy in preclinical mouse models [69]. Recently,
the ﬁrst trials of ipilimumab combinedwith the PD-1 blocking antibody
nivolumab in melanoma were completed, and showed that while the
combination achieves a striking increase in efﬁcacy – with 75% of pa-
tients experiencing objective responses – this enhanced efﬁcacywas ac-
companied by a concomitant increase in serious toxicities, with 53% of
patients experiencing grade 3 or 4 serious adverse events [10,11,70,
71]. Grade 3–4 toxicities were commonly characterized by elevated li-
pase, aspartate aminotransferase, and alanine aminotransferase levels,
indicating pancreas and liver toxicities. Unexpected side effects includ-
ing acute onset diabetes and diabetic ketoacidosis were noted in 17 pa-
tients co-treated with ipilimumab and nivolumab [72]. Often these
autoimmune adverse effects do not present until weeks to months
after treatment. Similar toxicities appear to be prevalent in a phase I
study of a different anti-CTLA-4 antibody (tremelimumab) in combina-
tion with an anti-PD-L1 antibody (durvalumab) tested in NSCLC pa-
tients [73]. Recently reported interim results of an ongoing phase II
trial of ipilimumab combined with nivolumab in recurrent small cell
lung cancer reported a lower incidence rate of serious side effects but
also lower levels of overall response [74]. Adjustment of dosing sched-
ules in a phase I study in non-small cell lung cancer patients (nivolumab
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given every 2weeks but ipilimumab given every 6 or 12weeks) showed
some reduction in toxicity compared to the initialmelanoma trials, with
only 33–37% grade 3–4 adverse events [75].
Combination treatment with checkpoint blockade antibodies epito-
mizes the promise and the challenge of immunotherapy – co-adminis-
tration of these agents systemically leads to signiﬁcant increases in
anti-tumor efﬁcacy, but also synergistic ampliﬁcation of toxicity.
Achieving the goal of long term durable remissions in a majority of pa-
tients is unlikely to be achieved by single drugs in difﬁcult-to-treat solid
tumors, and this has ledmuchof theﬁeld to be convinced of theneed for
combination immunotherapy strategies combining multiple drugs act-
ing via complementary mechanisms [76]. Solutions from the ﬁeld of
drug delivery may be critical to achieve this goal while avoiding life-
threatening toxicities that plaguemany immunotherapy drugs adminis-
tered using the systemic dosing strategies traditionally employed in
oncology.
2.3. Agonist antibodies against immune costimulatory receptors
CTLA-4 and PD-1 represent important inhibitory receptors that re-
strain T-cell priming and effector functions. These negative regulatory
receptors are counter-balanced by a suite of positive costimulatory re-
ceptors that support T-cell activation. Canonical examples include
CD28, CD137 (also known as 4-1BB), and CD134 (also known as OX40
or Tumor necrosis factor receptor (TNFR) superfamily member 4), but
like the negative regulatory receptors, a large collection of these recep-
tors (the TNFR superfamily) has been discovered. These proteins are
expressed by T-cells during activation by antigen presenting cells, and
bind to counter receptors expressed on the APC surface, providing sig-
naling synergistic to triggering of the T-cell receptor promoting T-cell
expansion, survival, and effector functions [77]. These receptors are
also expressed by other immune cells, such as natural killer cells. The
natural mode of costimulation from these receptors occurs at cell-cell
contacts, but this signaling can alternatively be induced by cross-linking
of costimulatory receptors on T cells by agonistic antibodies. This repre-
sents an additional strategy for immunomodulation, and antibodies di-
rected against costimulatorymolecules such as CD137, OX40, and CD28,
represent another class of promising cancer immunotherapies limited
clinically by systemic toxicity. Though capable of amplifying tumor-spe-
ciﬁc cytotoxic T cells, agonistic antibodies to T-cell costimulatory mole-
cules have on-target off-tumor effects due to the presence of their
ligands on non-tumor-speciﬁc T-cells and other immune subtypes, as
well as in some cases expression by other non-immune cell populations.
Off-tumor effects and deregulated production of proinﬂammatory cyto-
kines have led to dose limiting toxicities of both anti-CD137 and anti-
CD28 antibodies. Their mode of action- actively triggering intracellular
signaling rather than simply blocking a ligand-receptor interaction,
means that such antibodies function distinctly from the checkpoint
blockade antibodies described above. Antibodies are comprised of two
antigen-binding Fab domains and a rear Fc domain that can be bound
by Fc receptors (FcRs). Agonist antibodies against the TNFR superfamily
member CD40 have formally been shown to require an ability for their
Fc regions to bind Fcγ receptors for their activity in mice [78,79], sug-
gesting that the antibodies are “presented” from the surface of FcR-ex-
pressing cells and crosslink CD40 receptors on a neighboring cell in a
manner mimicking the natural cell-cell engagement in T-cell/APC con-
tacts (Fig. 1B). Similarly, agonist antibodies against OX40, CD137, and
CD27 require or show greatly enhanced activity if they are competent
for FcR binding [80,81].
CD137-targeting antibodies provide a useful case study of this class
of agonist antibody therapeutics. CD137 is expressed on the surface of
activated CD8+ T cells, and to a lesser extent on CD4+ T cells, natural
killer (NK) cells, NKT cells, regulatory T cells, dendritic cells, macro-
phages, neutrophils, and eosinophils [82]. In addition, this receptor
has been found to be expressed on vascular and lymphatic endothelial
cells at sites of inﬂammation and tumor vasculature [83–85]. Its natural
ligand, CD137L, is present on antigen presenting cells. As described
above, engagement of CD137 on T-cells by CD137L results in enhanced
T-cell proliferation, production of proinﬂammatory cytokines, and pro-
tection from activation-induced apoptosis [86]. Due to expansion of
memory T-cells directed against tumor antigen, administration of anti-
CD137 agonistic antibodies in preclinical mouse models has signiﬁcant
anti-tumor activity [87,88]. For example, mice treated solely with anti-
CD137 showed complete regression of tumors in a mastocytoma
model [89]. As a monotherapy anti-CD137 activates endogenous
tumor-reactive T-cells, but in combination with adoptive T-cell transfer
yielded 80% survival in a thymomamodel [87]. Similarly, combinations
of anti-CD137 with chemotherapy, irradiation, and tumor lysate pulsed
dendritic cells are also effective [90–92]. NK cell function is also en-
hanced by anti-CD137 therapy, though NK cells play an auxiliary role
to T-cells in the anti-tumor activity of anti-CD137 agonists [86,93]. Efﬁ-
cacy in most examined syngeneic mousemodels is dependent on CD8+
T-cells though CD4+ T-cells, NK cells, cross-presenting dendritic cells,
and IFN-γ productionwere proven to contribute in some tumormodels
[87,88,94].
Despite these promising therapeutic outcomes, anti-CD137 treat-
ment was noted to induce dysregulated hematopoiesis and liver dys-
function in preclinical murine studies. Increased T-cell inﬁltrates in the
liver, hepatitis, lymphopenia, thrombocytopenia, splenomegaly, hepa-
tomegaly, and lymphadenopathy have been reported [94]. Additional
side effects – namely alopecia, scaly skin, and increased AST and ALT
levels – appear more characteristic of systemic inﬂammation [95]. Sys-
temic cytokine release syndrome is also observedwith elevated system-
ic levels of proinﬂammatory cytokines such as IFN-γ, TNF-α, IL-12, and
type I interferons in mice treated with anti-CD137 monotherapy [93,
96]. TNF-α produced by CD8+ T-cells was shown to be critical in the de-
velopment of splenomegaly, lymphadenopathy, hepatomegaly, and
hepatitis. Conversely, IFN-γ and type I interferons contributed to the ex-
pansion of blood cells and mislocalization of T-cells, but were non-es-
sential to the overall development of toxicity. These toxicities are T-
cell- and CD137-dependent, as they are alleviated in Rag−/− and
CD137−/−mice [94]. Of note, the increasedmononuclear cell accumula-
tion in the portal areas of the liver was dependent on polyclonal T-cell
expansion: Due to the lack of oligoclonal T-cells in the liver, it is pre-
sumed that intra-liver T-cells are not directed against self-antigens
[96]. Localization of these cytotoxic cells to the liver contributes to apo-
ptosis of hepatocytes and subsequent hepatitis [94,96]. Themechanisms
governing anti-CD137 induced hepatotoxicity remain ill deﬁned;
however, preliminary evidence suggests IL-27 produced by anti-
CD137 stimulated myeloid subsets mediates the recruitment and acti-
vation of liver damaging T cells. Additionally, depletion of FoxP3+ reg-
ulatory T cells aggravates liver toxicity, suggesting a role for Tregs in
restraint of anti-CD137 initiated immune responses [97].
In spite of the adverse events in mice, studies by Bristol Myers
Squibb in cynomolgus monkeys demonstrated tolerability of the anti-
CD137 agonistic antibody urelumab, with no hepatic side effects at
doses up to 100 mg/kg, warranting a transition to human clinical trials
[98]. Urelumabwasﬁrst tested inmelanoma, non-small cell lung cancer,
and other advanced solid tumors [99]. During dose escalation of
urelumab, dose limiting grades 3 and 4 neutropenia were accompanied
by frequent yet mild adverse outcomes including leukopenia, thrombo-
cytopenia, and hyperbilirubinemia,mirroring toxicology results inmice.
In this study, partial remissions and stabilized tumor growth justiﬁed
further study of urelumab. Several clinical studies of urelumab in com-
bination with checkpoint blockade and other cancer treatments such
as chemotherapy and adoptive cell transfer have subsequently moved
forward, despite urelumab toxicities resulting from broad expression
of CD137 on many leukocyte populations (see clinicaltrials.gov). Most
adverse events from urelumab have beenmanagedwith corticosteroids
and anti-TNF-α antibodies; however, further clinical progresswith anti-
CD137will require a deeper understanding of themechanisms of toxic-
ity [100].
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Amore dramatic cautionary tale for agonistic antibodies can be found
in CD28 superagonists (CD28SAs). Preclinical studies in rats, non-human
primates, and cultures of human cells failed to predict nearly lethal cyto-
kine release syndrome in the six healthy volunteers ﬁrst dosed with
TeGenero's CD28SA TGN1412 [101]. Anti-CD28 superagonist antibodies
are capable of activating T-cells through the CD28 costimulatory receptor
in the absence of the classical “signal one” stimulus from peptide-MHC
binding the T cell receptor [102]. Crosslinking of CD28 using superagonist
antibodies led to proliferation of all subsets T-cells in mouse and rat
models [103]. In rodents CD28SAs also trigger the rapid expansion of
Tregs, allowing for potential applications in autoimmune disease in addi-
tion to cancer [104]. However, when applied in healthy human volun-
teers, the release of proinﬂammatory cytokines was so signiﬁcant that
all six patients were hospitalized, indicating major shortcomings in the
extensive preclinical research [105].
Six years of investigation were required to uncover the underlying
causes of the toxicity and why the adverse outcomes weren't predicted
preclinically. Ultimately, discrepancies between the clinical and preclin-
ical data were ascribed to 1) differences in the balance of Treg and T ef-
fectormemory cells in humans and rodents, 2) loss of CD28 in T effector
memory cells during CD4+ cell differentiation in primates but not
humans, and 3) failure of human PBMC culture conditions to adequately
recapitulate the tonic TCR signals foundwhen T-cells are present at high
densities promoting extensive cell-cell contacts as in lymphoid tissues
[105]. In mice, two waves of T-cell expansion arise after administration
of CD28SAs – theﬁrst a rise in conventional T cells and Tregs, the second
a Treg-exclusive expansion [106]. The limited number of expanded con-
ventional CD4+ T-cells and high percentage of Treg cells restrains an in-
ﬂammatory immune response in rodents. The twowavemodel does not
hold true in humans [107–109]. In humans, primarily CD4+ T effector
memory cells are activated upon CD28SA administration [110]. These
cells are tissue resident T-cells which accumulate over time to quickly
respond to antigen rechallenge. The activation of T effector memory
cells in humans without suppression by Tregs was one leading cause
of cytokine release syndrome. Accumulation of T effector memory
cells is common in humans which are constantly subjected to antigen
exposure whereas they are less prominent in mice housed in clean cag-
ing, thus explaining one difference between the preclinical and clinical
responses [110]. Eastwood et al. showed that CD4+T-cell differentiation
into T effector memory cells causes loss of CD28 expression in macaque
but not humans, explaining the inadequacy of the non-human primate
studies [110]. Lastly, testing of CD28SAs on human PBMC in culture did
not predict cytokine stormbecause PBMC grown in low density non-ad-
herent culture fail to recapitulate the tonic TCR signal present in T-cell
populations [111]. Treatment of high density human PBMC culture
with CD28SAs revealed enhanced proliferation of T-cells and proinﬂam-
matory cytokine production lacking in earlier studies. Cell-cell contacts
in these altered culture conditions allowed for minimal residual TCR ac-
tivation in T-cells required for the function of CD28 superagonists [111].
The development of CD28SAs demonstrates the difﬁculty is translating
safe immunotherapies from preclinical models to human trials.
Currently CD28SAs are not being clinically explored for cancer treat-
ment, however, the agonist described above (TGN1412) is undergoing
testing at lower doses for use in autoimmune diseases [112]. Newly de-
veloped human PBMC culture assays are utilized to test the compound,
now named TAB08. At 1000-fold lower concentrations than used in the
disastrous phase I clinical trial in 2006, TAB08 was well tolerated. At
these low doses, TAB08 is expected to induce expansion of Treg popula-
tions andproduction of anti-inﬂammatory cytokines like IL-10 for use in
autoimmune disease indications [112].
Altogether, similar to the checkpoint blockade antibodies, a general
conclusion in the development of agonist immunostimulatory antibod-
ies (and related recombinant agonist ligands) is that broad nonspeciﬁc
stimulation of all leukocytes (or other cell types) expressing any given
regulatory receptor is liable to be fraughtwith systemic toxicities arising
from on-target, off-tumor stimulation of cells in the blood or healthy
tissues. These observations motivate strategies to engineer control
over multiple facets of immune stimulation: what cellular subsets are
stimulated,where are they stimulated, and forwhat duration does stim-
ulation last.
2.4. Tumor targeting antibodies
Antibodies recognizing tumor antigens can also be utilized as immu-
nologic agents to promote tumor cell death. When directed against tu-
mors, antibodies can facilitate a host of effects both immune system-
dependent and –independent, including direct blockade of intracellular
signaling, induction of signaling-based apoptosis, enhanced sensitivity
to chemotherapy, complement mediated cytotoxicity (CMC), and anti-
body-dependent cellular cytotoxicity (ADCC) often mediated by NK
cells [113]. Inmany cases, evidence suggests antibodies originally devel-
oped to block oncogenic receptor signaling also act through immune-
dependent mechanisms. For example, trastuzumab is an approved
anti-human epidermal growth factor receptor type 2 (HER2) monoclo-
nal antibody; adjuvant administration of trastuzumab in breast cancer
patients results in a 23–35% increase overall survival [119]. HER2 is a
transmembrane tyrosine kinase receptor promoting a host of cellular
functions including proliferation through activation of the MAPK path-
way [114]. HER2 ampliﬁcation is detectible in approximately 30% of
human breast cancers; overexpression and mutations induce receptor
dimerization and near-constitutive activation of proliferation and anti-
apoptotic pathways [115,116]. Trastuzumab binds to the extracellular
portion of HER2, decreasing receptor dimerization and therefore intra-
cellular signaling, increasing endocytosis of HER2, and inhibiting shed-
ding of the extracellular domain of HER2 [117]. However, studies
regarding Fc receptor polymorphisms in cancer patients also suggest
that trastuzumab therapy may rely on immune effectors and ADCC by
NK cells and monocytes for efﬁcacy [118].
Many tumor targeting antibodies, trastuzumab included, have quite
favorable safety proﬁles, though rare incidences of grade 3 and 4 toxic-
ities have been noted. Trastuzumab, for example, is well-tolerated;
however, cardiotoxicity remains a concern due to on-target off-tumor
effects on HER2 expressing cardiomyocytes and cardiac stem cells
[120]. Cardiac dysfunction is prevalent in 8% of patients treated with
trastuzumab alone and increases to 30% in patients on concurrent
anthracyclines [121,122]. HER2 has been implicated in repair of
cardiomyocytes following anthracycline-induced and reactive oxygen
species induced damage, suggesting that combination of trastuzumab
with anthracyclines leads to on-target cardiac damage [123,124].
Cardiotoxicity ranges from decreased left ventricular ejection fraction
(LVEF) to congestive heart failure. Comparison of a short 6 month
trastuzumab regimen to a 12 month regimen reveals increased risk of
LVEF decline with longer exposure to trastuzumab, though more study
is needed to conﬁrm these results [125]. Meta-analysis of 10,000 pa-
tients determined a risk ratio of 5.11 (p ≤ 0.0001) for congestive heart
failure with trastuzumab compared to control populations [125].
While cardiotoxicity poses a serious threat to trastuzumab treated pa-
tients, identiﬁcation of risk factors and patient surveillance are likely
to limit treatment related deaths and hospitalizations [120].
Similarly, in the case of rituximab, an anti-CD20 human-mouse chi-
meric antibody developed for its ability to deplete CD20-expressing B
cells via CMC and ADCC in patients with B-cell lymphoma, toxicities
are typically mild, though serious adverse events are noted in a portion
of the patient population. Common grade 1 and 2 events include pruri-
tus, nausea, dizziness, and fevers. Serious infusion-related events such
as anaphylaxis and myocardial infarction have occurred after initial ri-
tuximab administration, though these side effects are rarely fatal and
can be managed with acetaminophen and antihistamines [126]. Addi-
tionally, increased rates of infection (8.1% of patients receiving rituxi-
mab, 3.9% in control arm) and neutropenia (13.4% of patients
receiving rituximab, 6.3% in control arm)were noted [127],with the for-
mer likely related to loss of normal B cells during rituximab treatment.
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Patients on a rituximab maintenance regimen also experienced more
infection-related adverse events compared to patients on observation
alone (Risk ratio 1.99) [128]. Grade 3 and 4 infection-related adverse
events all required hospitalization; patients on rituximab had more of
these severe events than the control population (Risk ratio 2.90)
[128]. Non-infection related respiratory adverse events including
cough, dyspnea, and sinusitis afﬂict 38% of patients receiving rituximab.
Meta-analysis of clinical studies up to June 2010 report 121 cases of ri-
tuximab-associated interstitial lung disease (ILD) characterized by dif-
fuse bilateral lung inﬁltrates and hypoxaemia with ILD fatalities
occurring in 18 patients [129]. Altogether, the side effects from tumor
targeting antibodies are generally mild and grade 3/4 adverse events
are rare, but the ability of antibodies to engage cellular components of
the immune system remains an issue that requires careful consideration
during antibody development, especiallywhen overexpressed self-anti-
gens present in healthy tissues are targeted.
2.5. Local administration of immunotherapy agents
One simple approach tomitigate immune toxicity has been the local
injection of immunomodulatory drugs directly into accessible lesions,
either primary tumors or metastases. Such an approach is predicated
on the expectation that locally-administered drugswill be preferentially
retained at the injected tumor site, and that such retentionmight be fa-
vored if concentrated local delivery allows the drug to be given at lower
doses than used systemically. Local injections have thus been explored
both preclinically and clinically for a variety of immunotherapy drugs.
Local therapy can be considered in any cancer where primary or meta-
static lesions are accessible either directly or through surgery, and thus a
great variety of tumors have been treated clinically through local thera-
py administration, for example melanoma, breast cancer, ovarian can-
cer, bladder cancer, lymphoma, and lung metastases in multiple
diseases [130–135].
Local administration of immunotherapy is motivated by the hypoth-
esis that the immune system, if stimulated locally, can disseminate from
the treatment site to attack other tumors which did not directly receive
any of the immunotherapy drug – if correct, this idea formalizes one of
the cardinal distinctions between immunotherapy and traditional
tumor-directed chemotherapy. Presently, several clinical andpreclinical
studies provide evidence in favor of this hypothesis. For many years, it
has been known that some patients who receive radiation therapy at
one selected tumor exhibit regressions of distal untreated lesions; this
phenomenon was termed the abscopal effect in the 1950s by Robert
Mole [136]. Only recently, as the role of the immune system in the re-
sponse to many traditional cancer therapies has become more clear,
was it demonstrated in preclinical mouse models that the abscopal ef-
fect is dependent on the host immune system [137], and that in fact ra-
diation treatment of tumors acts through the innate immune system to
amplify the adaptive immune response [138–140]. Similar abscopal-like
responses have now been reported in preclinical studies and clinical tri-
als of several types of immunotherapy: For example, local intratumoral
injection of an oncolytic virus combined with systemic anti-CTLA-4 led
to rejection of both treated and untreated tumors [141]. Intratumoral
injection of anti-CTLA-4 with the immune-agonist antibody anti-OX40
and the Toll like receptor agonist CpG led to depletion of regulatory T-
cells in the injected tumors, followed by systemic tumor regression
[142]. Phase I studies of intratumoral CpG combinedwith local radiation
therapy elicited partial responses in uninjected lesions of both lympho-
ma and mycosis fungoides patients [134,143]. Seung et al. found that a
combination of localized radiation treatment with systemic IL-2 inmel-
anomapatients led to a high proportion of complete or partial responses
(74%), correlating with expanded CD4+ T-cell responses in the periph-
eral blood [144]. These are just a few examples of systemic responses to
local immunotherapy, which has also been termed intratumoral vacci-
nation or in situ vaccination based on the concept of the treated
tumor itself serving as a source of antigens for priming new T-cell re-
sponses in draining lymph nodes [145–148].
Local immunotherapy thus has clinical relevancy for both primary
and metastatic disease; however, intratumoral injection of free thera-
peutics does not necessarily limit systemic exposure to toxic immuno-
therapies. Compounds injected into the intratumoral/peritumoral
space may reach systemic circulation via lymphatic drainage or by di-
rect access through leaky tumor vasculature. By deﬁnition, such system-
ic dissemination raises the potential for systemic toxicity mirroring
direct intravenous administration. For example, intratumoral injections
of agonist antibodies or cytokines in mouse models of solid tumors has
resulted in the rapid appearance of high serum concentrations of these
agents [43,149,150]. The dissemination of these compounds into the
systemic circulation can result in signiﬁcant weight loss, systemic cyto-
kine storms, and even lethality from systemic immunotoxicity [43].
Intratumoral administration also does not provide persistent stimula-
tion at the tumor site; for example 48 h after intratumoral injection of
an agonistic anti-CD40, the antibodywas nearly undetectable in tumors
by immunohistochemistry [149]. Similarly, intratumoral or peritumoral
injections of other cytokines, antibodies, and TLR agonists have all been
shown to lead to systemic dissemination of these agents and often, sys-
temic toxicity in mouse models [149–152]. These preclinical results
echo ﬁndings in the clinic: In phase I studies of recombinant IL-12 and
TNF-α, patients receiving intratumoral injections showed the recombi-
nant cytokines at high levels in plasmawithin 30min after injection, in-
dicating a lack of local retention [153,154]; systemic levels of IFN-γ and
IL-10 and fever-like systemswere elevatedwithin 4–8 hours post-injec-
tion and did not return to background levels for 48 h [154]. Other stud-
ies of intratumorally-injected cytokines where dissemination of the
drug was not characterized reported toxicities equivalent to systemic
injections, suggesting systemic exposure [155]. Trials of low doses of
IFN-γ injected intratumorally have shown good safety proﬁles, but
also lacked efﬁcacy, whichmay reﬂect the low doses and/or poor reten-
tion of the therapeutic in the injected lesions [156]. Thus, local injection
is a well characterized strategy to alter the pharmacokinetics of drug
treatments, but this simple approach does not fully isolate immunother-
apies from the systemic circulation. Taking full advantage of abscopal-
like effects of immunotherapies while mitigating systemic toxicities re-
quires strategies to locally target and retain drugs in the tumor
microenvironment.
3. Engineering safer local therapies
The previous two sections highlight a variety of challenges associat-
ed with the yin and yang of efﬁcacy vs. toxicity in both systemic and
local immunotherapy. Though it is clear that dosing parameters have a
signiﬁcant impact on safety and therapeutic outcome [157], these chal-
lenges often cannot be solved by optimizing dosing and timing alone
(e.g., lowering dose increases safety but lowers efﬁcacy). Drug delivery
technologies provide many potential solutions to these issues. While
enhancing the safety of systemic immunotherapies is important, we
ﬁrst discuss the conceptually simpler problem of enhancing the safety
and efﬁcacy of local immunotherapy. A key objective is promoting bet-
ter local retention of immunotherapeutics and blocking their dissemi-
nation into the circulation. Approaches include the use of local drug
depots that match release rates of drugs to their uptake by target im-
mune/tumor cells, blocking therapeutic diffusion through locally-
injected biomaterial anchors, and conﬁning therapeutics to tumors
through localized intratumoral gene delivery (e.g., using oncolytic
viral vectors). We discuss in turn examples of each of these approaches
applied to immunotherapy. The use of drug delivery technologies to en-
hance the safety of cancer vaccine formulations, e.g., through enhanced
delivery to lymph nodes or targeting of speciﬁc APC populations, is a
subject of much research effort, but as this topic could ﬁll a review on
its own, we have chosen to focus on treatments focused on the tumor
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or tumor-draining lymph nodes, and refer interested readers to other
recent reviews on the subject of vaccine technologies [158–162].
3.1. Intratumoral drug depots
Because many immunotherapy toxicities (e.g., vascular leak syn-
drome) are linked to systemic stimulation of circulating leukocytes
and/or direct action of immunomodulators on endothelial cells, an obvi-
ous strategy to enhance local therapy is to better conﬁne therapeutics to
a chosen target lesion. One way to achieve this is through local con-
trolled release of drug from intra- or peritumorally injected drug deliv-
ery matrices (Fig. 2A). One of the ﬁrst demonstrations of this approach
waswork by Egilmez et al. seeking to improve on the safety and efﬁcacy
of IL-12 as an immunotherapeutic [163,164]. IL-12's potent anticancer
effects are limited by dose- and temporal regimen-dependent toxicity
when administered systemically [165,166]. Egilmez showed that a sin-
gle intratumoral (i.t.) injection of biodegradable polylactic acid micro-
spheres exhibiting controlled release of IL-12 was safe and led to
complete regression of transplanted lung tumors, prevented metastatic
spread to the lung, and enabled animals to reject a subsequent re-chal-
lenge with live tumor cells, indicating the development of systemic an-
titumor immunity [163]. More recently, chitosan matrices have been
similarly used to provide sustained localized dosing of IL-12 in several
tumor models, including as a neoadjuvant treatment in a breast cancer
model prior to surgical resection of the primary tumor [167–169].
Hanes et al. used crosslinked gelatin/chondroitin sulfate microspheres
as delivery vehicles for intratumoral delivery of IL-2 in models of brain
or hepatic melanoma metastases [151]. IL-2 delivered by these micro-
spheres persisted in tumors for 3 weeks, compared to only 24–48 h
for bolus-injected drug. At the same time, bolus-injected IL-2 was
found in the blood, spleen, and other organs minutes after bolus i.t. in-
jection of IL-2, while microsphere-delivered cytokine led to very low
or undetectable cytokine outside of the tumor microenvironment.
Hori et al. designed self-crosslinking alginate gels [170] and used these
to provide sustained local release of IL-15 following peritumoral injec-
tion [150]. This strategy lowered the systemic exposure to the cytokine
by ~2-fold and increased the dosingwithin the tumor 40-fold relative to
a bolus injection of IL-15.
Checkpoint blockade antibodies have also been shown to beneﬁt
from localized slow-release delivery at tumors. Peritumoral injection
of water-in-oil emulsions (Montanide) containing anti-CTLA-4 allowed
a low dose of the checkpoint blockade antibody to effectively drive anti-
tumor immunity while providing greatly decreased systemic exposure
and reduced liver toxicity compared to traditional systemic anti-CTLA-
4 dosing [152]. Recently,Wang et al. developed dissolvingmicroneedles
that deposited slow-release dextran nanoparticles into melanoma le-
sions in the skin [171]. These particles dissolved in response to local tis-
sue glucose mediated by incorporated glucose oxidase, releasing anti-
PD-1 in a sustained manner that enhanced survival in treatment of
B16F10 tumors. A similar microneedle-based transdermal patch was
applied to synergistically co-deliver anti-PD-1 and an inhibitor of the
immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) to
mouse melanoma, achieving effective T cell immunity and reduced im-
munosuppression in the local site (Fig. 3A i–iii) [172].
Intratumoral depots of cytokines or checkpoint blockade antibodies
primarily act to enhance the action of a pre-existing immune response
against tumors. Another approach is to create intratumoral depots of
agents aiming to promote de novo tumor killing, antigen capture and
priming of new T-cell responses by tumor-localized immune cells
using innate immune stimulating “danger signals”. Imidazoquinolines
are a class of small molecule drugs that bind to Toll like receptors
(TLRs) 7 and 8, promoting dendritic cell andmacrophage activation. In-
jection of unformulated forms of these compounds leads to rapid dis-
semination into the blood and systemic cytokine storm signatures
[173,174]. However, acylated forms of these TLR agonists can be formu-
lated into liposomes or oil/water emulsions for localized retention in tis-
sue [173,175]. Singh et al. demonstrated that an acylated TLR7 agonist
delivered in an oil emulsion into solid tumors could both arrest the
growth of the treated tumor and prime a disseminated immune re-
sponse that attacked distal, untreated tumors [175].
Related to these intratumoral treatments, another strategy is to in-
troduce controlled-release biomaterials into a tumor resection site,
with the goal of stimulating local immunity to residual tumor cells in
the absence of the bulk immunosuppressive factors derived from a
large primary tumor: Stephan et al. used alginate gels as a matrix for
co-delivery of tumor-speciﬁc T-cells and mesoporous silicon micropar-
ticles to resection sites of primary breast tumors. The microparticles
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Fig. 2. Strategies for enhancing localized immunotherapy. (A) Synthetic particles/matrices administered directly to accessible lesions can provide sustained local dosing of
immunomodulatory drugs with greatly lowered systemic exposure. Local immune activation leads to tumor cell death in the treated tumor and tumor antigen delivery to the TDLN,
priming new T-cell responses that return to the treated tumor as well as disseminate to attack other metastases that were not directly treated. (B) Nanoparticles can be used to safely
target immunomodulators to the TDLN, activating tumor antigen-loaded dendritic cells to prime T-cell responses that disseminate to attack tumors systemically.
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Fig. 3. Strategies for enhancing local delivery of immunotherapy. (A)(i) Microneedle-based delivery platform containing self-assembled nanocarriers (m-HA or NP) loaded with IDO
inhibitor 1-MT and anti-PD-1. (ii) Immunoﬂuorescence comparison of anti-PD-1/1-MT nanocarrier loaded microneedles and free anti-PD-1/1-MT loaded microneedles in tumors days
post drug administration. (iii) B16F10 tumor growth versus time for 1-MT and anti-PD-1 delivered from microneedles (MN) as free drugs or encapsulated within nanocarriers (NP).
Reproduced with permission from [172]. (B)(i) Retention of anti-CD137 and IL-2Fc-conjugated liposomes (white) within subcutaneous B16F10 tumors 24 h after intratumoral
injection. (ii) Cryosection of ﬂuorescently labeled immuno-liposomes in the TDLN. (iii–iv) Serum levels of anti-CD137 and IL-2Fc 18 h following intratumoral injection in soluble or
liposome-bound form. Reproduced from [43] with permission. (C) Conjugation of CpG and antigen to PPS nanoparticles improves the efﬁcacy of a TDLN-targeted cancer vaccine. (i)
7 days after E.G7-OVA tumor inoculation, ﬂuorescently labeled nanoparticle-conjugated OVA and CpG were delivered intradermally ipsilateral or contralateral (ii) to the tumor and
presence of signal was analyzed 24 h later in the brachial lymph node. (iii) Tumor volume versus time with nanoparticle delivery of antigen and adjuvant to the tumor draining lymph
node. (iv) Resulting antigen speciﬁc T-cell frequency following lymph node draining vaccine. Reproduced from [198] with permission.
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carried anti-CD3/CD28 stimulators for T-cells and slowly released IL-15,
providing localized TCR and cytokine support for the T-cells and leading
to elimination of tumor recurrence that was not achieved if T-cells were
administered systemically or lacking the matrix of supporting factors
[176]. Thus, a number of approaches can be used to augment local im-
munotherapy while improving safety proﬁles of immunoregulatory
drugs through local controlled release materials.
3.2. Intratumoral gene delivery
An alternative approach to slow-release depots of immunotherapy
drugs is to locally produce the agent of interest through gene transfec-
tion in the tumor microenvironment. This is perhaps best exempliﬁed
by oncolytic viral vectors, viruses which speciﬁcally replicate within
tumor cells and promote tumor cell death, often in tandemwith expres-
sion of immunomodulatory proteins delivered in the viral genome.
Talimogene Laherparepvec (T-Vec), a granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF)-encoding oncolytic herpes simplex
virus, is the ﬁrst example of this strategy to receive FDA approval, in
the setting of metastatic melanoma. T-vec is administered by direct
intratumoral injection, and was shown to trigger complete regression
of both injected and uninjected lesions in 16% of treated patients, sug-
gesting intratumoral administration of an oncolytic virus can effectively
cross-prime and amplify antitumor immunity [177,178]. In this setting,
GM-CSF expression from infected tumor cells is thought to promote the
chemoattraction and differentiation of dendritic cell precursors to the
tumor site, combined with immunogenic tumor cell death leading to
enhanced presentation of antigen to prime new T-cell responses against
the tumor. Similarly, intratumoral injections of escalating doses of a
GM-CSF-expressing vaccinia virus to patients with cutaneous melano-
ma or non-hepatocellular carcinoma, result in favorable immune re-
sponses and tumor regression [179,180]. These intratumorally-
injected viruses only spread locally within the tumor microenviron-
ment due to their large size, and do not spread systemically to distant
sites of tumor growth. Thus, the systemic toxicity observed has been in-
frequent and rapidly resolving [179].
Therapeutic efﬁcacy can be achieved through intratumoral injection
of viruses, DNA, or RNA expressing immunoregulatory factors even
without direct oncolytic activity of the nucleic acid vector. For example,
i.t. injection of an adenovirus or alphavirus expressing IL-12 induced
highly localized cytokine expression in tumors, leading to tumor regres-
sion and long-term immunity [181,182]. Intralesional injection of adeno-
virus encoding human CC chemokine ligand (CCL) 16 inhibited
mammary tumor growth and prevented metastatic spread in mice bear-
ing 4T1 mammary adenocarcinoma [183]. Polyplexes of DNA plasmids
encoding IL-2 and folate-targeted polyethyleneimine-cyclodextrin were
shown to be an effective and safe therapy for melanoma in mice, with
an efﬁcacy comparable to that of recombinant adenoviruses expressing
IL-2 (rAdv-IL2) [184]. In clinical studies, intratumoral injection of naked
DNA encoding cytokines (IL-2, IL-12) has shown some clinical beneﬁts
for melanoma patients [185,186]. A particularly promising approach is
to combine localized tumor microenvironment modulation through
intralesional gene or oncolytic virus delivery with systemic administra-
tion of checkpoint blockade antibodies or other immune modulators
with known/acceptable systemic toxicities, enabling an immune response
primed by local therapy to be protected as it disseminates to attack un-
treated lesions [141]. Thus, a variety of vectors and approaches are
being explored for local expression of immunostimulatory cytokines
and chemokines in tumors.
3.3. Anchored drugs
The examples above are based on releasing immunomodulators at
controlled rates within tumor sites, which can only avoid systemic ex-
posure if release rates are in careful balance with drug consumption/
degradation rates in the tumor. An alternative is to deliver
immunotherapy agents into the tumor microenvironment bound to
particles, synthetic matrices, or extracellular components of the tumor
microenvironment itself that present these molecules to surrounding
immune cells but physically prevent their free diffusion out of the
tumor site. An early example of this strategy utilized the injection
of lipidated recombinant costimulatory receptors to “paint” tumors
with a costimulatory ligand that would promote T-cell recognition
of tumor cells [187,188]. Insertion of the lipid tail of these recombi-
nant proteins into the membranes of tumor cells following
intratumoral administration led to retention of these proteins at
the tumor site, enabling engineering of tumor cell recognition by
immune cells or induction of chemotactic signals to recruit more
immune effectors to the tumormicroenvironment. Lipid conjugation
to DNA oligonucleotides has similarly been used to anchor
immunostimulatory CpG DNA (a TLR9 agonist) in tumors, promoting
retention in the microenvironment that improved the safety proﬁle
and efﬁcacy of intratumoral CpG therapy [189].
A secondapproach to “anchoring” therapeutics in the tumor is to uti-
lize nanoparticles not for their capacity to home to tumors spontane-
ously but rather for their tendency to become entrapped in the tumor
ECM following intratumoral injection. This approach has been demon-
stratedwith combinations of potent cytokines and innate immune stim-
ulators. As noted in Section 2, both IL-2 and anti-CD137 elicit potent
antitumor immune responses, but their clinical use is limited by inﬂam-
matory toxicities upon systemic administration. These toxicities are fur-
ther ampliﬁed in combination treatment with these drugs, which elicits
lethal systemic toxicities even following intratumoral administration at
therapeutic doses [43]. To block the systemic dissemination that drives
this toxicity, Kwong et al. conjugated anti-CD137 and an engineered IL-
2-Fc fusion protein to the surface of PEGylated liposomes. Intratumoral
injection of these immunoliposomes restricted the immunotherapeu-
tics to the tumor and tumor-draining lymph nodes, but completely
blocked their entry into the systemic circulation by virtue of physical
trapping of the liposomes in the tumor extracellular matrix (Fig. 3B i–
iv). Treatment with these particles eliminated injected primary tumors,
elicited systemic antitumor immunity, and eliminated systemic inﬂam-
matory toxicity compared to equivalent intratumoral doses of soluble
immunotherapy. A similar approach was used to deliver liposome-an-
chored anti-CD40 and CpG intratumorally, leading to signiﬁcant tumor
growth inhibition and enhanced survival similar to their soluble coun-
terparts after intratumoral injection, while avoiding systemic exposure
[149]. Immunotherapy agents may also be intrinsically nanoparticulate
in nature, promoting their local retention following intratumoral injec-
tion. For example, Lizotte et al. used cowpea mosaic viruses for in situ
vaccination of tumors [190]. Although the precise mechanism remains
to be deﬁned, these plant virus-derived nanoparticles stimulated
intratumoral inﬂammation that led to a systemic anti-tumor immune
response. Thus, particulate immunostimulatory therapies administered
intratumorally can signiﬁcantly decrease or eliminate systemic inﬂam-
matory side effects, while retaining the anti-tumor efﬁcacy of free solu-
ble drugs.
3.4. Tumor draining lymph node-targeted drugs
Besides the tumor itself, tumor-draining lymph nodes (TDLNs, or
sentinel lymph nodes) are of interest as a target for localized immuno-
modulatory drugs, because despite evidence for lymphatic dysfunction
in some tumor models, TDLNs are known to accumulate antigens from
dying tumor cells that could be used to prime de novo anti-tumor T-
cell responses. However, tumor-induced dendritic cell dysfunction
within TDLNs is a known mechanism of immune evasion [191,192].
Concentration of innate immune-stimulatory adjuvants within sentinel
lymph nodes allows for the activation and maturation of dendritic cells
exposed to tumor-associated antigen while preventing cytokine storm-
like symptoms which occurs from systemic administration of these
agents [193,194]. Local injections near a tumor can be used to target
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TDLNs through the local lymphatic tree (Fig. 2B). Lymphatic drainage
from the interstitial space is highly dependent on molecule or particle
size. Small particles b30 nm diam. injected intradermally can be found
within 50% of lymph node-resident dendritic cells, while larger
100 nm particles only reach 6% of the same population, suggesting
that larger particles may be engulfed by phagocytic cells prior to
lymph localization and/or impeded in convection through the ECM
[195,196]. Conversely, while small particles can traverse through
dense interstitial matrix to directly reach the lymph nodes, they may
not be retained within lymphoid organs – as evidenced by signiﬁcant
blood concentrations of 30 nm sized particles 12 hours post-intrader-
mal injection [197]. Therefore, favorable lymphatic localization is reliant
upon a balance of drainage from the injection site and capture within
local lymph nodes.
Exploiting these principles, Jeanbart et al. synthesized 25 nm diam.
pluronic-stabilized poly(propylene sulﬁde) (PPS) nanoparticles capable
of concentrating within TDLNs following intradermal injection [198].
These nanoparticles are carried via interstitial ﬂow from the injection
site into lymphatic capillary beds and from there to TDLN-resident den-
dritic cells. Conjugation of the TLR9 agonist CpG DNA to these particles
elicited activation of dendritic cells in tumor draining lymph nodes,
and primed anti-tumor adaptive immune responses in murine
thymoma and melanoma models, while limiting systemic pro-inﬂam-
matory responses (Fig. 3C i–iv) [198]. CpG has also been targeted to
tumor draining lymph nodes through association with cationic gelatin
nanoparticles and cationic polyethylenimine (PEI) coated poly(lactic-
co-glycolic acid) (PLGA) nanoparticles, alone and in combination with
IL-10 siRNA [199–201]. TLR7/8 agonists have also been successfully de-
livered to tumor draining lymph nodes in nanoparticle format to focus
the production of pro-inﬂammatory cytokines within the site of T cell
priming and prevent systemic inﬂammation [173,202].
In addition to size-dependent trafﬁcking of drug through lym-
phatics, molecular targeting to dendritic cells which migrate to and re-
side within lymph nodes has improved the safety and efﬁcacy of
immunotherapies. Cruz et al. describe in detail dendritic cell targeting
via DEC205, CD11c, and CD40 dendritic cell receptors [162]. Lymph
node targeting by physical, chemical, and molecular properties has
been extensively studied for applications in both prophylactic and
therapeutic vaccines as vaccination depends on the delivery of antigen
and adjuvant to these sites of immune cell education [161].
4. Engineering safer systemic immunotherapies
The administration of immunotherapy agents systemically is de-
sired for treatment of metastatic disease, but faces limitations due to
non-tumor-targeted stimulation of leukocytes and other cell types
expressing immunoregulatory receptors. An ongoing challenge is
the design of strategies to deliver immune-modulating drugs to
appropriate immune cells in target tissue sites (e.g., tumors and
tumor-draining lymph nodes) while minimizing non-speciﬁc sys-
temic stimulation.
4.1. Molecularly-targeted immunotherapy
A common strategy to target therapeutics to tumors employs conju-
gation of drug to a tumor-antigen speciﬁc ligand, antibody, or other
engineered binding molecule to achieve local accumulation of the
drug following systemic delivery. The fusion of pro-inﬂammatory cyto-
kines to tumor-associated antigen speciﬁc antibodies, known as
immunocytokines, represents a common approach to direct the deliv-
ery of cytokines to the tumor microenvironment. Cytokines can be
fused to either the N or C termini of heavy or light chains of IgG mole-
cules (Fig. 4A and B) [203]. In these formats, functions of the antibody
such as antigen binding, interactionwith Fc receptors, and participation
in the complement cascade can be maintained. Alternatively, cytokines
can be fused to diabodies or single chain variable fragment (scFv) anti-
bodies to solely maintain the antigen binding property of the antibody
(Fig. 4C–E). One proposed mechanism of action of immunocytokines
is the bridging of tumor cells to leukocytes [204–207]. In the case of
IL-2 immunocytokines, the antibody interacts with tumor surface anti-
gens while the IL-2 binds to the IL-2 receptor (IL-2R) on T-cells and
NK cells, thereby promoting their proliferation and effector function in
the tumormicroenvironment. Antibody-dependent cellular cytotoxicity
(ADCC) afforded by interactionwith the Fc domain of the antibody com-
ponent has also been shown to be important for the efﬁcacy of
immunocytokines [208]. Finally, immunocytokines have longer blood
Fig. 4. Tumor targeting with immunocytokines. (A–E) Immunocytokine formats based on IL-2, IL-12, and TNF-α. (A) IgG format with IL-2 cytokine covalently linked at the c-terminus of
the heavy or (B) light chains. (C) Diabody fusion protein featuring IL-2. (D) Homotrimeric scFv-TNF fusion protein. (E) Heterodimer featuring scFv fused to p40 and p35 subunits of IL-12.
Reproduced from [203] with permission. (F) Biodistribution of TA99-IL-2 immunocytokine of format (A) targeting Trp-1melanoma antigen inmice bearing subcutaneous B16F10 tumors.
24hours post injection of Alexa Fluor 647-labeledproteins, organsweredissociated into single cell suspensions and stained for immune lineagemarkers. D265A indicates amutation in the
Fc portion of TA99 abrogating interaction with Fc receptors. The sm3E antibody targeting carcinoembryonic antigen is an irrelevant antibody in model. This irrelevant immunocytokine
features similar biodistribution to the melanoma-targeted TA99 immunocytokine. Used with permission from [210].
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half-lives compared to the parent cytokine molecules due to their in-
creased size and endocytic recycling of the fusion protein through the
Fc neonatal receptor [209]. This enhanced half-life enables
immunocytokines to be administered at decreased doses, which in
some cases enhances their safety proﬁle [210].
Antibody-targeted cytokines have shown promising results in pre-
clinical mouse models of cancer. The immunocytokine hu14.18-IL2, a
fusion of two molecules of IL-2 with an antibody (14.18) recognizing
the GD2 disialoganglioside expressed on the surface of melanomas
and neuroblastomas [211], has shown enhanced anti-tumor activity in
preclinical melanoma models than equivalent amounts of un-fused
14.18 antibody and IL2 [212]. In a study of 33 melanoma patients,
hu14.18-IL2 given as 4-hour intravenous infusion daily for three days
resulted in an increase in lymphocyte counts, NK lysis, and ADCC
when peripheral blood samples were monitored. Immunocytokines
have also been targeted to components of the extracellular matrix
overexpressed in the tumor microenvironment. For example, F8-IL2,
an immunocytokine based on the F8 antibody in diabody format allows
for targeting of IL-2 to the alternatively spliced extra-domain A of ﬁbro-
nectin in the lung tumor microenvironment [213]. F8-IL2 was shown to
selectively localize at the tumor site in vivo following intravenous ad-
ministration, and to mediate tumor growth retardation of non-small
cell lung cancer [213]. Other common tumor environment targets in-
clude ﬁbronectin extra-domain B, which is highly expressed in tumor
vasculature, tenascin C A1 domain, an alternatively spliced form of the
tenascin glycoprotein in angiogenic vasculature, and extracellular
DNA, found frequently as a result of cell death in the necrotic cores of
tumor [211,214–219].
Clinically, immunocytokines have shown improved efﬁcacy and re-
duced toxicity compared to soluble pro-inﬂammatory cytokines; how-
ever, the fusion protein format does not abrogate systemic toxicity.
Following IL-2 as a model case, hu14.18-IL2 elicits dose limiting toxic-
ities of hypoxia, hypotension, hyperglycemia, and elevated ALT and
AST levels [220]. While toxicity was reduced relative to parental IL-2
therapy, patients treatedwith the hu14.18-IL2 immunocytokine still ex-
perienced dose limiting toxicities [221]. Recently, Tzeng et al. demon-
strated that a major factor limiting the efﬁcacy and safety of
immunocytokines is the dominant role played by binding of the fusion
protein to circulating cytokine receptor-expressing leukocytes in the
blood, prior to arrival in tumors [210]: A single injection of a fusion of
themelanoma-targetingmonoclonal antibody (mAb) TA99with IL-2 la-
beled 2% of tumor cells, while an equimolar dose of the parental anti-
body labeled 40% of tumor cells. Further, replacing TA99 with another
antibody (sm3E) targeting carcinoembryonic antigen (CEA), an onco-
fetal antigen not present in the tumor line used, revealed that antigen
speciﬁcity was dispensable for the limited tumor targeting observed
for the immunocytokine. Loss of tumor targeting by themAb-IL-2 fusion
was due to dominant uptake of the fusion protein by circulating IL-2 re-
ceptor-expressing immune cells including DCs, NK cells, NKT cells,
CD8+ T-cells, and Tregs, indicating that the cytokine rather than the
tumor antigen-speciﬁc antibody component of the immunocytokines
dictated its in vivo cellular biodistribution (Fig. 4F) [210]. From this
case study, it is clear that the immunocytokine format can be important
for reducing the toxicity of proinﬂammatory cytokines, but the
“targeting” behavior of both components of the fusion must be consid-
ered to understand the ultimate biodistribution. An alternative is to ad-
minister immunocytokines directly into the tumor microenvironment
through intralesional injection, using the tumor-binding antibody com-
ponent to enhance retention of the cytokine in the local site. This ap-
proach has shown promise in melanoma, and allowed high doses of a
tumor matrix-binding IL-2 immunocytokine to be administered
intratumorally with minimal systemic toxicity [133].
In addition to directing cytokine to the tumor microenvironment,
tumor-targeted antibodies have also been used to home innate immune
stimulatory danger signals to tumors. In a mouse model of pancreatic
cancer, CpG DNA (TLR9 agonist) conjugated to an antibody directed
against the tumor antigenmucin-1 reduced tumor burden via activation
of Natural Killer (NK) cells and promotion of ADCC [222]. CpG-antibody
conjugates have also been formulated to target CD20on B cells for appli-
cations in non-Hodgkin lymphoma and the Her2/neu receptor found in
Her2 positive breast cancers [223]. This approach has also been used
with other danger signals including polyinosine/polycytosine (pIC, a
TLR3 agonist), which was successfully targeted to EGFR- and HER2-
overexpressing tumors. Schrand et al. generated bispeciﬁc aptamers
that bound vascular endothelial growth factor, a product of tumor stro-
ma, and agonized CD137 [224]. Systemic administration of these
aptamers elicited tumor regression in multiple tumor models with
lower toxicity than untargeted CD137-binding aptamers or anti-
CD137 antibodies. Natural ligands for receptors overexpressed by
tumor cells can also be used to guide immunomodulators to tumors.
For example, a ternary conjugate of epidermal growth factor, melittin
(a peptide promoting cytosolic delivery), and PEG coupled to a
polyethyleneimine backbone was complexed with pIC to deliver the
TLR agonist to EGFR-overexpressing cells, resulting in apoptosis and in-
ﬂammation in the tumor site [225,226].
4.2. Nanoparticle delivery of immunotherapy agents to tumors
Targeting toxic compounds to tumors has historically been pursued
as a strategy to increase the efﬁcacy and limit systemic toxicity of cancer
therapeutics. To this end, much effort has been invested in the develop-
ment of nanoparticles that passively promote the accumulation of small
molecule chemotherapies and targeted drugs in tumors [227,228]. This
nanomedicine approach is based on the concept of the enhanced per-
meability and retention (EPR) effect, which predicts that particles of a
suitable size (large enough to avoid clearance from the blood through
the kidneys but small enough to avoid rapid ﬁltration by the reticuloen-
dothelial system) can enter tumors through their leaky vasculature, and
accumulate due to defective lymphatic drainage [229,230]. The efﬁcien-
cy of the EPR effect in heterogeneous human tumors has been debated
[231], but nanomedicine-based immunotherapy approaches remain of
signiﬁcant interest because potent immunoregulatory drugs can be ac-
tive at doses much lower than chemotherapy or anti-tumor targeted
drugs (e.g., kinase inhibitors), and do not need to accumulate in every
tumor cell for their mode of action.
A number of studies have explored the use of nanoparticles to con-
centrate immunotherapy drugs in tumors. PLGA-PEG block copolymer
nanoparticles ~80 nm in diameter were used to promote accumulation
of the kinase inhibitor sunitinib in tumors, which among other activities
inhibits the key immunosuppressive transcription factor STAT3 [232].
Nanoparticle delivery of the inhibitor led to a pro-immune remodeling
of the tumormicroenvironment that synergizedwith therapeutic vacci-
nation in a murine melanoma model [233]. With similar goals in mind,
it has also been shown that delivery of siRNA targeting the immunosup-
pressive cytokine TGF-β to tumors using lipid/protamine/hyaluronic
acid nanoparticles led to knockdown of TGF-β in tumors but not
lymph nodes, and reversed accumulation of Tregs andMDSCs in tumors
following therapeutic vaccination [234]. To mitigate the systemic side
effects of intravenously administered checkpoint blockade antibodies,
cationic polymeric nanoparticles have been used to deliver siRNA
targeting CTLA-4 to tumors, thus targeting the checkpoint blockade in-
hibition to tumor inﬁltrating lymphocytes [235]. Here, siRNA was com-
plexed with a cationic surfactant and encapsulated in poly(ethylene
glycol)-block-poly(D,L-lactide) nanoparticles, providing the size require-
ments for tumor accumulation, and leading to reduced CTLA-4 expres-
sion by tumor-inﬁltrating lymphocytes.
Another advantage of nanoparticle drug delivery is the capacity to
co-deliver multiple factors to the same cell/tissue site, and this feature
has been demonstrated to be particularly useful for immunotherapy.
To exploit the synergy of providing immune-stimulatory signals togeth-
er with blockade of immunosuppressive pathways, Fahmy and col-
leagues generated liposome-encapsulated nanogels capable of co-
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Fig. 5.Nanoparticles for systemic immunotherapy. (A)(i) Photoinduced polymerization of nanoscale liposomal polymeric gels forms a core-shell structure of biodegradable polymer (red)
with a PEGylated liposomal coating (grey) capable of co-encapsulating IL-2 cytokine (green) and coated TGF-β inhibitor, SB505 (blue). (ii) Biodistribution of rhodamine loaded nanoscale
liposomal gels and soluble rhodamine following a single injection intomicewith euthanasia timepoints of 1, 24, 48, and 72hours post-injection. (iii) Accumulation of rhodamine following
peritumoral injection of rhodamine loaded nanoscale liposomal gels in B6 mice. (iv) Subcutaneous tumor area versus time. Used with permission of [236]. (B)(i) Pluronic-stabilized
poly(propylene sulﬁde) (PPS) nanoparticles of 25 nm but not 100 nm are detectable in lymph nodes 24 h after injection. (ii) Quantiﬁed ﬂow cytometric analysis of CD11c+ dendritic
cells that have internalized ﬂuorescently labeled PPS nanoparticles. (iii) Nanoparticle-positive percentages of cells found in organs and lymph nodes 12 h after intradermal injection.
Ax: axillary, Br: brachial, In: inguinal, Po: popliteal; Sp: spleen, Bl: blood, Kd: kidneys, Li: liver, Lu: lungs. (iv) Flow cytometry of monocytic (MO) and polymorphonuclear (PMN)
MDSCs from E.G7-OVA tumor bearing mice injected with Dy649-labeled PPS nanoparticles. (v) Quantiﬁcation of nanoparticle accumulation in MO-MDSCs and PMN-MDSCs of the
tumor draining lymph node (TDLN), non-TDLN, spleen, and tumor. Used with permission from [195,197]. (C)(i) Schematic of T cell functionalization with SN-38 chemotherapy loaded
nanocapsules and homing to sites of lymphoma. (ii) Retention of SN-38 chemotherapeutic in tumor draining lymph nodes. Free SN-38 was given at a 10-fold lower dose than in the
nanocapsule conditions. Used from [250] with permission.
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delivering both a small molecule hydrophobic TGF-β inhibitor and
water-soluble IL-2 (Fig. 5A i) [236]. These nanolipogels enhanced the ef-
ﬁcacy of IL-2/TGF-β inhibitor co-therapy both as intratumoral agents
and administered i.v. for direct targeting of melanoma metastases, in-
creasingNK cell activity and intratumoral-activated CD8+ T-cell inﬁltra-
tion [236]. Enhanced anti-tumor activity and survival was achieved by
these particles without eliciting evidence for systemic toxicity or lung
tissue damage (in the case of treating lung metastases) (Fig. 5A i–iv).
Micellar nanocarriers comprised of PEG and stabilizing Fmoc chemical
moieties were used to co-deliver the chemotherapeutic paclitaxel and
indoleamine 2,3-dioxygenase (IDO) inhibitor to the tumor microenvi-
ronment in both breast cancer and melanoma models. Co-delivery re-
sulted in cytotoxic effects in the tumor by paclitaxel and a reversal of
tumor immune suppression by the IDO inhibitor yielding a signiﬁcant
survival beneﬁt [237].
It has recently become appreciated that nanocarrier accumulation in
tumors is often mediated by uptake of particles in phagocytic myeloid
cells [197,238,239]. These myeloid populations include tumor-associat-
ed macrophages and myeloid-derived suppressor cells, which support
tumor growth and have numerous mechanisms of promoting immuno-
suppression [240]. Particle accumulation in these tumor-associated
populations provides another strategy for nanomedicine-mediated im-
munotherapy. For example, sub-100 nm sized pluronic-stabilized
poly(propylene sulﬁde) (PPS) micelles administered intradermally
drain through the lymphatic system to tumors, tumor draining lymph
nodes, and the spleen (Fig. 5B i and ii). These polymeric nanoparticles
are efﬁciently taken up by myeloid-derived suppressor cells in lym-
phoid organs and tumors (Fig. 5B iii–v) [197]. Loading of PPS particles
with 6-thioguanine, a purine analog capable of depleting MDSCs, en-
hanced the efﬁcacy of adoptive T-cell immunotherapy in two mouse
models through reprogramming of the immunosuppressive cellular
tumor microenvironment [239]. Some nanomaterials may also have in-
trinsic immunomodulatory effects on myeloid cells: Dextran-coated
iron oxide nanoparticles are FDA-approved therapeutics for treatment
of iron deﬁciency [241]. Recently, it has been shown that such nanopar-
ticles, which accumulate in tumors, are capable of repolarizing macro-
phages from an immunosuppressive M2 phenotype to M1 subtypes,
leading to TNF-α production and inducing formation of reactive oxygen
species through Fenton reactions with the iron oxide [242–244]. Huang
et al. exploited elevated expression ofmacrophage galactose-type lectin
receptor to target galactosylated polyplexes of cationic dextran com-
plexed with alginate, CpG DNA, and anti-sense oligonucleotides against
IL-10 and IL-10 receptor to tumor-associated macrophages [245]. To
overcome the problem of promiscuous expression of target receptors
by myeloid cells in other tissue compartments, Zhe et al. designed
PLGA nanoparticles carrying both mannose (to target the mannose re-
ceptor expressed broadly by macrophages) and acid-cleavable PEG
chains [246]. Shedding of the acid-labile PEG chains in the acidic
tumormicroenvironment was proposed to promote enhanced accumu-
lation in tumors followed bymannose-mediated targeting to TAMs; en-
hanced colocalization of particles functionalized with both sheddable
PEG and mannose was demonstrated in B16F10 melanomas.
The safety of immune-stimulating nanomedicine can be augmented
by following nanoparticle delivery with exogenous localized activation
of a therapeutic at the tumor site. Examples of “remote” activation of
therapeutics include photodynamic and photothermal therapies,
where photosensitive compounds are activated by tissue-penetrating
light to produce local radical species or heating that cause damage to
tumor tissues. For example, PLGA nanoparticles carrying the
phototheramlly-active dye indocyanine green were delivered systemi-
cally, followed by localized near-infrared light of a tumor to stimulate
localized energy absorption by the dye, subsequent heating, and
tumor ablation [247]. This photothermal therapy generated a local
depot of tumor antigen, which functioned as an in situ vaccine when
combined with co-delivery of a TLR agonist adjuvant and checkpoint
blockade inhibitors.
The EPR effect ismediated by particle size, and thusmacromolecules
can also exhibit EPR-mediated accumulation in tumors. Nektar is devel-
oping an immunotherapy prodrug, NKTR-214, which uses sheddable
PEG chains linked to IL-2 to promote tumor accumulation and limit
early “bolus” activation of systemic IL-2 receptors following infusion of
the PEGylated cytokine [248]. NKTR-214 is IL-2 linked to releasable
PEG chains conjugated near residues in the IL-2:IL-2Rα binding pocket,
which initially prevent interaction of the IL-2moleculewith thehigh-af-
ﬁnity IL-2 receptor-α chain (CD25). NKTR-214 accumulates in tumor
sites and serves an IL-2 reservoir as the PEG chains hydrolyze with
half-lives of 20 h per chain. In the B16F10 mouse melanoma model,
NKTR-214 provided a 500-fold greater tumor exposure to IL-2 as well
as dose sparing compared to soluble IL-2. This cytokine prodrug was
well tolerated in mice and non-human primates, with no vascular leak
syndrome detected at maximum tolerated doses, unlike soluble IL-2
[248]. In a related approach, Puskas et al. generated masked IL-2 mole-
cules formed by fusing IL-2 to a soluble form of the IL-2Rα chain
through a peptide linker containing a motif recognized by tumor-asso-
ciated proteases [249]. Similar to PEGylated IL-2, this fusion protein is
designed to limit systemic stimulation and localized active IL-2 to the
tumor site. This fusion had some anti-tumor activity but was not com-
pared to systemic free IL-2.
4.3. Systemic gene delivery of immunomodulators to tumors
An alternative to physical targeting of immunomodulators to the
tumor microenvironment is to deliver genes encoding these factors.
As noted in Section 3.2, oncolytic viruses that preferentially replicate
in tumor cells and co-express immunoregulatory cytokines are under
intense study, and theﬁrst example of this class of immunotherapies re-
cently received FDA approval [251]. However, expression of
immunocytokines by viruses administered systemically has been
found to lead to signiﬁcant toxicity in animalmodels, due to early trans-
fection events occurring outside of tumors (e.g., in the spleen), which
lead to transient but highly toxic systemic cytokine expression outside
of tumors [42,44]. Banaszynski et al. developed a promising strategy
to overcome this issue: these investigators fused a destabilizing do-
main, a mutant of the FK506- and rapamycin-binding protein, to a
cytokine of interest [252]. When transfected into cells this intrinsi-
cally unstable domain leads to constitutive degradation of the fusion
protein by the proteasome. However, in the presence of a small mol-
ecule drug (termed Shld-1) that binds to the peptide, the fusion pro-
tein is stabilized, secreted, and has bioactivity [252]. Using this
approach, it was shown that an oncolytic virus encoding either
tumor necrosis factor-α or IL-2 could be safely delivered intrave-
nously, with immunoctyokine expression activated by administra-
tion of Shld-1 a few days later, when viral expression is conﬁned to
transfected tumors [42,44]. This approach is an elegant and general
strategy that should be compatible with many types of oncolytic
viruses and synthetic nucleic acid delivery vectors under study for
cancer immunotherapy.
4.4. Immune cells as drug carriers
A variety of cellular therapies based on the injection of autologous
immune cells primed for anti-tumor activity are in preclinical and clin-
ical development. Immunotherapies based on the adoptive transfer of
autologous tumor-speciﬁc T cells (adoptive cell therapy, or ACT) have
been shown to be effective in hematologic cancers and a subset of
solid tumors [4,253]. Clinical trials are also underway using adoptively
transferred natural killer cells [254]. In preclinical studies, adoptively
transferred macrophages have been shown to migrate to and accumu-
late in tumors [255]. These ﬁndings have motivated studies of a second
strategy for focusing immunotherapies on speciﬁc sites or immune cells,
using transferred immune cells themselves as living drug carriers [256].
These approaches, while clinically much more complex to implement
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than the simple injection of a drug or nanoparticle construct, have a sig-
niﬁcant advantage over drug delivery mediated by convective diffusion
or the EPR effect: while traditional drug targeting is hampered by vari-
ation in tumor vasculature, lymphatics, ECM content and interstitial
pressures both within a single tumor and between different tumor
types [229,257], cell-mediated targeting of therapy has the potential
to overcome these heterogeneities and disseminate drugs throughout
tumor tissue through the active processes of cellular extravasation
from blood vessels and migration.
A ﬁrst approach is based on the concept of employing immune cells
as active chaperones to deliver immunotherapeutics to tumors based on
their intrinsic tissue homing patterns. For example, MDSCs are actively
recruited from the circulation by tumors to promote active suppression
of anti-tumor immunity [240,258,259]. Eisenstein et al. demonstrated
that MDSCs loaded with a oncolytic vesicular stomatitis virus (VSV)
(using a non-neutralizing anti-VSV antibody to link the viral particles
to the cells through MDSC Fc receptors) efﬁciently home to hepatic
lung tumor metastases following adoptive transfer into tumor-bearing
mice [258]. MDSC-mediated delivery enabled the VSV vector, which
had no therapeutic efﬁcacy as a systemically-administered agent
alone, to cure 80% of treated animals. This approach has also been
employed with adaptive immune cells: T-cells expressing CD62L and
CCR7 naturally home to lymph nodes, a primary site of lymphoma/leu-
kemia accumulation and a common site for metastasis of many solid tu-
mors. Exploiting this natural trafﬁcking pattern, Qiao et al. used naive T-
cells with surface-adsorbed VSV to chaperone the oncolytic virus into
lymphoid organs harboring metastatic tumor cells. Adoptive transfer
of virus-loaded T-cells effectively reduced metastatic tumor burden
and vaccinated the affected individual against micrometastatic disease
via the release of immunostimulatory tumor antigens in situ [260].
Using synthetic nanoparticles as the therapeutic payload, Huang et al.
conjugated T-cells with drug-loaded lipid nanocapsules as vehicles to
ferry the chemotherapy agent SN-38 to tumor-ridden lymph nodes in
a murine model of disseminated lymphoma. These “backpacked” T-
cells signiﬁcantly re-directed the biodistribution and pharmacokinetic
proﬁles of SN-38 in vivo, enabling anti-tumor efﬁcacy at doses of drug
that showed no systemic toxicity. T-cell-mediated delivery conferred a
90-fold greater SN-38 accumulation in lymph nodes comparing to free
drug systemically administered at 10-fold higher doses, leading to sig-
niﬁcantly reduced tumor burden and enhanced survival; while free
SN-38 and SN-38-loaded nanocapsules alone were ineffective (Fig. 5C
i and ii) [250].
A variation on the use of cell-intrinsic homing programs is to load
immune cells with particles that permit external guidance, e.g., using
magnetic ﬁelds: Muthana et al. recently described a strategy to direct
cells carrying an oncolytic virus to tumors using magnetic resonance
imaging (MRI)-based magnetic guidance: Exploiting their phagocytic
capacity, macrophages were loaded ex vivo with magnetic iron oxide
nanoparticles, followed by infection with an oncolytic HSV vector. Fol-
lowing i.v. injection, a pulsed magnetic ﬁeld gradient was applied by
MRI to provide a magnetic force promoting accumulation of the iron-
loaded macrophages at primary or metastatic tumor sites, leading to a
~6-fold increase in donor cell accumulation throughout tumors. While
injection of free oncolytic virus led to only minor inhibition of tumor
growth, substantial sustained tumor growth blockade was achieved
through magnetic ﬁeld-mediated targeting of iron oxide-loaded infect-
ed macrophages to tumors [261].
A third strategy is to payload immunotherapy agents on tumor-spe-
ciﬁc T-cells, which instead of relying on an intrinsic tissue-homing pro-
gram accumulate in tumors following recognition of tumor antigen
with their T-cell receptors. In adoptive cell therapy (ACT), the effector
function of infused activated T-cells often undergoes rapid decay due
to the highly immunosuppressive environment in tumors. Systemic ad-
ministration of supporting adjuvant immunomodulators together with
ACT T-cells has been used to boost the function of infused ACT T-cells,
but these simultaneous adjuvant treatments are often accompanied by
serious toxicities, especially cytokine storms that have caused patient
deaths in multiple clinical trials [262,263]. As an alternative to systemic
adjuvant drug therapy, Stephan et al. conjugated nanoparticles loaded
with interleukin cytokines or immunosuppression-blocking drugs to
the surface of ACT T-cells ex vivo prior to transfer into tumor-bearing re-
cipients (Fig. 6). These T-cell-bound particles provided autocrine drug
delivery to the transferred T-cells while minimizing systemic exposure
to these inﬂammatory signals, leading to enhanced efﬁcacy of drug-
modiﬁed ACT T-cells and reduced systemic toxicity in multiple cancer
models [264,265]. This strategy is currently in commercial/clinical
Ex vivo drug loading
Molecular targeting to 
circulating or tumor 
resident immune cells
Nanoparticle 
trafficking to tumor
Molecular targeting of 
drug to tumor
Fig. 6. Targeting immunomodulators to tumors or immune cells. Overview of strategies for targeted delivery of immunotherapy: Molecular or nanoparticle targeting can be directed to
circulating immune cells or directly to the tumor; alternatively, nanoparticles can be payloaded ex vivo on immune cells for adoptive transfer.
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translation by Torque Pharmaceuticals. In a similar vein, Prussian blue
nanoparticles (PBNPs) that exhibit photothermal responsiveness were
conjugated to Epstein-Barr virus (EBV)-speciﬁc CD8+ T-cells, to enable
homing of these photothermal agents to EBV-associated tumor malig-
nancies [266]. Wayteck et al. designed a reversible coupling strategy
linking siRNA-carrying liposomes to the surface of CD8+ T cells via di-
sulﬁde bonds [267]. Levels of reductants such as glutathione are low
in the circulation, but tumors are thought to be a thiolytic milieu
[268], providing the potential for speciﬁc release of these cell-bound
particles in the tumor microenvironment. To enhance the delivery of
viral vectors for immunotherapy, Cole et al. adsorbed viruses encoding
IL-12 or Herpes Simplex Virus thymidine kinase (HSVtk) to the cell sur-
face glycosaminoglycans of tumor antigen-speciﬁc T-cells. These retro-
viral vectors could release from T-cell surfaces at the tumor site after
in vivo cell transfer, leading to productive infection of tumor cells. This
strategy protected the therapeutic viral particles from neutralization
in circulation, and allowed virus to speciﬁcally accumulate at the sites
of antigen expression, providing high levels of selectivity for viral trans-
fer to metastatic tumors [269]. Altogether, these various approaches to
surface engineering of T-cells showmuch promise for enhancing adop-
tive cell therapy of cancer.
4.5. Targeting immunotherapy to immune cells
Payloading immunotherapy agents on leukocytes during adoptive
cell therapy provides exquisite control over the initial state of the cells
and their cargo, but does not allow for repeated or serial stimulation
of the transferred cells. An alternative is to target immunotherapy
agents directly to immune cells in vivo. Immune cell targeting is moti-
vated not only by the requirement for many immunomodulatory
drugs to act directly on leukocytes, but also by the fact that many im-
mune cell populations recirculate through the blood or are present at
high densities in the spleen, sites efﬁciently accessed by intravenous ad-
ministration that avoid the multiple and heterogeneous barriers to
accessing cells deepwithin tumors. Careful selection of targeting strate-
gies can enable such systemic immune cell targeting to both enhance ef-
ﬁcacy and improve the safety proﬁle of immunotherapy drugs.
As already discussed, immunoregulatory cytokines naturally target
their cognate receptors on lymphocytes but often stimulate a broad
range of immune cell subsets and may stimulate non-immune cells,
complicating their safe therapeutic use. One approach to this challenge
is to engineer cytokines to confer narrowed target cell speciﬁcities, al-
tering the intensity and/or duration of signaling to mitigate toxicity
[270]. This strategy has been extensively studied with IL-2: T-cells, NK
cells, endothelial cells, and Tregs each have distinct expression patterns
for the 3 chains (α, β, and γ) of the IL-2 receptor. Complexation of IL-2
with an anti-IL-2 antibody that blocks the IL-2Rα binding site but leaves
theβ andγ chain epitopes accessible allowed IL-2 to be redirected away
from stimulating endothelial cells and Tregs, focusing its action on effec-
tor T-cells and NK cells and greatly reducing vascular leak syndrome in
mice [22,271]. Protein engineering has also been used to redesign IL-2
for enhanced binding to the IL-2R β chain, creating an IL-2 “superkine”
exhibiting greatly enhanced stimulation of cytotoxic T-cells, while un-
expectedly also achieving lower induction of pulmonary edema in
vivo [272]. This latter beneﬁcial side effectmight reﬂect preferential up-
take of the superkine by circulating CD8+ T-cells. Other lymphocyte
targetingmodalities are in development, including aptamers that target
surface molecules to directly modulate T-cell function. Berezhnoy et al.
generated aptamer-siRNA conjugates where the aptamer binds to
CD137 on activated T-cells and delivers siRNA to knock down expres-
sion of the keymetabolic regulatormTOR, leading to enhancedmemory
generation during therapeutic cancer vaccination against tumors [273].
Another approach to controllably target lymphocyte subpopulations is
to combine molecular targeting with extrinsic therapeutic activation.
This approach was impressively demonstrated by Sato et al., who
targeted a near infrared-photoactivated radical-generating
photodynamic drug to regulatory T-cells via an anti-CD25 targeting an-
tibody [274]. Although this targeting moiety systemically labels Tregs
and activated T-cells, within immunosuppressive tumors the only cells
expressing high levels of CD25 are Tregs. By applying NIR light to an ac-
cessible tumor, depletion of intratumoral Tregs and induction of sys-
temic immunity was demonstrated, with only brief systemic
inﬂammation – in stark contrast to the lethal autoimmunity that ensues
when Tregs are systemically depleted [275].
Bispeciﬁc antibodies bearing variable domains that bind to a tumor
antigen and CD3, a key signaling component of the T-cell receptor com-
plex, have been developed to redirect endogenous T-cells against tu-
mors– enabling in theory T-cells of any antigen speciﬁcity to be
stimulated on contact with a bispeciﬁc-decorated tumor cell. The ﬁrst
such Bispeciﬁc T-cell Engager (BiTE), an anti-CD19/anti-CD3 bispeciﬁc
called Blinatumomab, was recently approved for treatment of acute
lymphoblastic leukemia [276]. Similar BiTE molecules are in preclinical
and clinical development targeting antigens expressed by a variety of
solid tumors, leukemias, and lymphomas [277]. Shen et al. reported on
a strategy to create a modular and drug-regulatable form of
multispeciﬁc T-cell engager based on self-assembled nanorings [278].
In this system, eight copies of a dihydrofolate reductase (DHFR) dimer
fused to a single-chain antibody are assembled into a nanoscale ring
structure through DFHR binding to bismethotrexate. By self-assembling
DHFR dimers fused to an anti-CD3 and an anti-tumor antibody, bi- or
multi-speciﬁc constructs are obtained that can bind to T-cells and
prime them for rapid and high level effector responses on recognition
of tumor cells [278].
Nanoparticle drug carriers can also be targeted to adoptively trans-
ferred or endogenous lymphocytes. Using PLGA particles as an analog
to BiTEs, Schütz et al. showed that nanoparticles bi-functionalized
with an antibody targeting a tumor cell surface antigen together with
a peptide-MHC complex to target pre-existing memory T-cells could
be used to redirect inﬂuenza-speciﬁc memory T-cells against lympho-
mas in a humanized mouse model [279]. This approach may have ad-
vantages relative to CD3-targeting BiTEs, by allowing speciﬁc memory
T-cell populations to be targeted that could be selected for known favor-
able effector proﬁles (e.g.,ﬂu or CMV-speciﬁc T-cell populations). Zheng
et al. functionalized PEGylated liposomes with IL-2 or antibody frag-
ments targeting an isoform of Thy1 uniquely expressed by adoptively-
transferred T-cells, to assess the ability of immunoliposomes to be
targeted to ACT T-cells [280]. A single injection of immunoliposomes la-
beled nearly 100% of circulating target T-cells, with low off-target bind-
ing. IL-2-functionalized liposomes served not only to target the vesicles
to transferred T-cells but also could be repeatedly injected to directly
stimulate the transferred cells following transfer. Frick et al. coupled re-
combinant IL-2 to the surface of hydroxyethyl starch nanocapsules via
copper-free click coupling, and demonstrated speciﬁc T-cell targeting
in vitro and in vivo by IL-2 receptor-mediated internalization [281].
Use of Thy1-targeting to direct liposomes carrying a small molecule
TGF-β inhibitor to ACT T-cells allowed doses of the drug that had no ef-
fect when administered systemically as a free drug to enhance the T-
cells' anti-tumor activity [282]. Recently, single-walled carbon nano-
tubes functionalized with antibodies targeting the GITR receptor
(expressed at particularly high levels on intratumoral Tregs) were
used to target intratumoral Tregs preferentially over peripheral Tregs
in the spleen, relying on a combination of the EPR effect and ligand-me-
diated targeting [283]. These materials might serve as the basis for
targeting speciﬁc depletion of intratumoral Tregs, with the goal of
achieving therapeutic effects similar to anti-CTLA-4 therapy without
systemic autoimmunity.
Immunotherapies have also been targeted to innate immune cells to
enhance anti-tumor activity. The strategy of piggybacking oncolytic vi-
ruses on immune cells described in the previous section has recently
been extended to direct in vivo loading of antibody-opsonized oncolytic
viruses onto myeloid cells that home to tumors. Monocytes and macro-
phagesmobilized from the bonemarrow by a systemic injection of GM-
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CSF (an approved cytokine therapy [284,285]) were found to bind op-
sonized virus injected after the cytokine, and subsequently homed
into tumors and transfer virus to the tumor cells [286]. Neutrophils
can also home to tumors in some settings. Chu et al. targeted photody-
namic drugs and other therapeutics to circulating neutrophils using
nanoparticles formed from denatured albumin. By administering a
monoclonal antibody against gp75 antigen expressed in melanoma tu-
mors, neutrophils were recruited to the tumors, bringing the albumin
nanoparticle-associated drugs to the tumor site [287]. Smith et al. re-
cently reported an unexpected strong tropism of i.v.-injected single-
walled carbon nanotubes for circulating Ly-6Chi cells, which subse-
quently transported the internalized SWNTs to tumors [288]. This
tumor homing by monocytic cells was further enhanced when SWNTs
were functionalized with the integrin-binding peptide RGD, which per-
haps may reﬂect selective targeting of the SWNTs to cells primed for
tumor homing. Such an innate cell-selective nanomaterial could be
well suited to delivery of immunomodulatory drugs to the tumormicro-
environment. Exploiting the fact that tumors attract myeloid-derived
suppressor cells to promote immunosuppression, Kullberg et al. devel-
oped a method to target MDSCs using endogenous activated comple-
ment C3 of tumor bearing animals [289]. PEGylated liposomes bearing
an orthopyridyl disulﬁde were injected intravenously, which will react
with the exposed sulfhydryl of activated C3, leading to binding and up-
take by C3 receptor-expressing granulocytic MDSCs present at high
levels in the blood of tumor-bearing animals and patients [289]. Use of
an endogenousmolecule tomediate targeting avoids issues of immuno-
genicity and stability that can occur using antibodies and other
engineered targetingmolecules. These examples illustrate the potential
for ﬁne-tuned targeting of circulating immune cell populations as a po-
tentially very powerful approach to obtain potent anti-tumor activity of
immunotherapeutics while mitigating immunotoxicity.
5. Conclusions and future perspectives
As summarized here, many approaches founded in rational con-
trolled drug delivery technologies offer promise for simultaneously en-
hancing the efﬁcacy and safety of immunotherapies for cancer. This
includes strategies based on protein and genetic engineering, controlled
drug deliverymaterials, and nanomedicine. As with any cancer therapy,
a key to achieving optimal results will be ﬁnding the right marriage of
these approaches to achieve robust activity of immunoregulatory
drugs while avoiding on-target/off-tumor toxicities. There remain a
number of challenges/opportunities in the ﬁeld- two examples being
limitations of animal models and further improving on strategies to
control the targeting of immunotherapy drugs. For example, a limitation
of current animal models is their limited capacity to reliably predict the
toxicity proﬁle that will be observed in human patients. Mice are the
predominant preclinical species used to evaluate candidate cancer im-
munotherapies, and while mouse models have been successfully used
to guide the development of all of the currently approved immunother-
apy drugs, the immune toxicity proﬁles of many agents in mice are
clearly distinct from humans. For example, anti-CTLA-4 in mice does
not elicit the same level of gastrointestinal toxicity observed in humans,
and mice tolerate a number of immune agonist compounds better than
humans. One solution to this issue could be increased use of humanized
mousemodels to study immunotherapy, but humanizedmousemodels
do not yet fully recapitulate the complete range of functions of an intact
healthy immune system [290] and have largely been used only for test-
ing adoptive cell therapy treatments where engineered T-cells are in-
fused into animals lacking any other human immune system
components. Other groups are seeking to improve the predictive
power of murine immunotherapy models by using partial regulatory
T-cell depletion to make animals more susceptible to autoimmune
side effects observed in patients [291]. Improvements in animal models
will be a key part for future success in the development of treatments
that maximize the potential of immunotherapy.
A second challenge/opportunity is the potential for immunother-
apies to be enhanced by leveraging promising strategies developed in
other areas of drug delivery to the problems of immune-modulatory
drugs. As one example, the systemic exposure and/or limited efﬁcacy
often observed following local bolus injection of immunotherapies is a
characteristic of many biologic therapeutics that have minimal interac-
tions with the extracellular matrix, which exhibit rapid tissue diffusion
and/or proteolysis. However, other signaling proteins such as cytokines
and chemokines have the ability to interactwith binding sites presented
by ECM proteins and cell surface proteoglycans, providing a means to
sequester or retain these factors following secretion in tissue [292]. Bio-
material matrices are being developed to mimic these key characteris-
tics of the ECM, including those that are derived from naturally
occurring molecules and those that recapitulate key motifs of biomole-
cules. For instance, the 12th–14th ﬁbronectin type III region (FN III12–
14) can bind a variety of cytokines with high afﬁnity, without blocking
their activity [293]. Matrix-binding variants of FN III12–14 have been
designed as universal binding anchors for cytokine retention inmatrices
for the application of tissue engineering and regenerative medicine, im-
proving efﬁcacy, safety, and cost-effectiveness for growth factor deliv-
ery [292] – such approaches should be of interest for modulating local
immunotherapies. Conversely, immunotherapy agents are being de-
signed to bind efﬁciently to tumormicroenvironment ECM components
to retain therapeutics locally, as demonstrated recently for engineered
growth factors designed to be retained locally in tissue regeneration
sites [294]. The advent of controlled delivery properties in a single mo-
lecular entity is attractive for clinical translation.
Altogether, there is reason to hope that within the foreseeable fu-
ture, immunotherapy-based treatments will lead to the transition of
cancer from a fatal diagnosis to a chronic, manageable disease, if not
curable condition for a large number of patients. Strategies as discussed
in this reviewwill likely play a major role in helping the ﬁeld attain this
goal of enhanced survival with a high quality of life for cancer patients
worldwide.
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